https://trial.medpath.com/news/nextgen-class-of-2025-and-m-a-uptick-predicted 2025-01-08T10:48:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nextgen-class-of-2025-and-m-a-uptick-predicted 2025-01-08T10:48:16+00:00 hourly 0.9 https://trial.medpath.com/news/alzheimer-s-drug-discovery-foundation-invests-record-10m-in-alamar-biosciences-for-blood-based-diagnostic-platform 2025-01-08T10:47:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alzheimer-s-drug-discovery-foundation-invests-record-10m-in-alamar-biosciences-for-blood-based-diagnostic-platform 2025-01-08T10:47:11+00:00 hourly 0.9 https://trial.medpath.com/news/sana-biotechnology-s-up421-therapy-shows-promising-results-in-type-1-diabetes 2025-01-08T10:47:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sana-biotechnology-s-up421-therapy-shows-promising-results-in-type-1-diabetes 2025-01-08T10:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/zhengye-biotechnology-raises-6-9-million-in-ipo-to-expand-veterinary-vaccine-portfolio 2025-01-08T10:41:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/zhengye-biotechnology-raises-6-9-million-in-ipo-to-expand-veterinary-vaccine-portfolio 2025-01-08T10:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/iros-and-halia-therapeutics-launch-pioneering-obesity-clinical-trial-in-uae 2025-01-08T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iros-and-halia-therapeutics-launch-pioneering-obesity-clinical-trial-in-uae 2025-01-08T10:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/positive-fda-feedback-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-01-08T09:41:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/positive-fda-feedback-for-phase-ii-trial-of-tiprelestat-in-pulmonary-arterial-hypertension 2025-01-08T09:41:32+00:00 hourly 0.9 https://trial.medpath.com/news/micron-biomedical-advances-needle-free-vaccine-technology-with-43-million-in-funding 2025-01-08T09:37:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/micron-biomedical-advances-needle-free-vaccine-technology-with-43-million-in-funding 2025-01-08T09:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/comparative-study-on-cefoxitin-administration-methods-for-preventing-surgical-site-infections 2025-01-08T09:35:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comparative-study-on-cefoxitin-administration-methods-for-preventing-surgical-site-infections 2025-01-08T09:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/alyssum-therapeutics-expands-series-a-funding-with-femhealth-ventures-participation 2025-01-08T09:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alyssum-therapeutics-expands-series-a-funding-with-femhealth-ventures-participation 2025-01-08T09:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/senate-investigation-reveals-concerning-impact-of-private-equity-ownership-on-healthcare-quality-and-safety 2025-01-08T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senate-investigation-reveals-concerning-impact-of-private-equity-ownership-on-healthcare-quality-and-safety 2025-01-08T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/experienced-industry-leader-dr-joerg-moeller-appointed-as-chief-executive-officer-of-antag-therapeutics 2025-01-08T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/experienced-industry-leader-dr-joerg-moeller-appointed-as-chief-executive-officer-of-antag-therapeutics 2025-01-08T09:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/physiomics-plc-announces-approval-for-predict-onc-clinical-trial 2025-01-08T09:02:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/physiomics-plc-announces-approval-for-predict-onc-clinical-trial 2025-01-08T09:02:38+00:00 hourly 0.9 https://trial.medpath.com/news/oxford-s-novel-blood-test-shows-95-accuracy-in-early-cancer-detection-across-six-cancer-types 2025-01-08T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oxford-s-novel-blood-test-shows-95-accuracy-in-early-cancer-detection-across-six-cancer-types 2025-01-08T08:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-prostate-cancer-imaging-technique-shows-promising-results-in-clinical-trials 2025-01-08T08:43:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-prostate-cancer-imaging-technique-shows-promising-results-in-clinical-trials 2025-01-08T08:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/aca-enrollment-hits-historic-23-6-million-as-enhanced-subsidies-face-2025-expiration 2025-01-08T08:24:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aca-enrollment-hits-historic-23-6-million-as-enhanced-subsidies-face-2025-expiration 2025-01-08T08:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/global-workplace-wellness-market-sees-substantial-growth 2025-01-08T08:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-workplace-wellness-market-sees-substantial-growth 2025-01-08T08:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/genmab-s-rybrevant-lazcluze-combination-shows-superior-survival-benefits-in-egfr-lung-cancer 2025-01-08T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genmab-s-rybrevant-lazcluze-combination-shows-superior-survival-benefits-in-egfr-lung-cancer 2025-01-08T08:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-nmpa-approves-padcev-in-combination-with-keytruda-for-advanced-urothelial-cancer 2025-01-08T07:30:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-nmpa-approves-padcev-in-combination-with-keytruda-for-advanced-urothelial-cancer 2025-01-08T07:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/aer-therapeutics-doses-first-patient-in-phase-2-clinical-trial-for-copd-treatment 2025-01-08T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aer-therapeutics-doses-first-patient-in-phase-2-clinical-trial-for-copd-treatment 2025-01-08T07:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/cambridge-cognition-s-cantab-plays-key-role-in-schizophrenia-drug-approval 2025-01-08T07:28:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cambridge-cognition-s-cantab-plays-key-role-in-schizophrenia-drug-approval 2025-01-08T07:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-announces-promising-data-for-bi-1910-as-single-agent-from-phase-1-study-in-solid-tumors 2025-01-08T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-announces-promising-data-for-bi-1910-as-single-agent-from-phase-1-study-in-solid-tumors 2025-01-08T07:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/allurion-s-audacity-trial-achieves-one-co-primary-endpoint-misses-another 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/allurion-s-audacity-trial-achieves-one-co-primary-endpoint-misses-another 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/proteomic-analysis-reveals-new-insights-into-semaglutide-s-mechanism-of-action 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/proteomic-analysis-reveals-new-insights-into-semaglutide-s-mechanism-of-action 2025-01-08T07:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/25-of-patients-recruited-in-guard-therapeutics-phase-2b-pointer-study 2025-01-08T07:05:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/25-of-patients-recruited-in-guard-therapeutics-phase-2b-pointer-study 2025-01-08T07:05:28+00:00 hourly 0.9 https://trial.medpath.com/news/global-study-projects-mixed-trends-in-childhood-atopic-dermatitis-through-2050 2025-01-08T07:00:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-study-projects-mixed-trends-in-childhood-atopic-dermatitis-through-2050 2025-01-08T07:00:52+00:00 hourly 0.9 https://trial.medpath.com/news/azafaros-receives-orphan-drug-designations-for-nizubaglustat-in-gm1-gangliosidosis-treatment 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/azafaros-receives-orphan-drug-designations-for-nizubaglustat-in-gm1-gangliosidosis-treatment 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bioinvent-reports-promising-early-results-from-triple-combination-therapy-for-non-hodgkin-s-lymphoma 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bioinvent-reports-promising-early-results-from-triple-combination-therapy-for-non-hodgkin-s-lymphoma 2025-01-08T07:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ryght-ai-partners-with-qps-holdings-to-transform-clinical-trial-operations-using-ai-technology 2025-01-08T06:28:17+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ryght-ai-partners-with-qps-holdings-to-transform-clinical-trial-operations-using-ai-technology 2025-01-08T06:28:17+00:00 hourly 0.9 https://trial.medpath.com/news/in-home-rehabilitation-shows-promise-despite-healthcare-system-barriers 2025-01-08T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/in-home-rehabilitation-shows-promise-despite-healthcare-system-barriers 2025-01-08T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/yale-surgeon-scientist-secures-fda-orphan-drug-designation-for-pembrolizumab-in-rare-respiratory-disease 2025-01-08T05:45:12+00:00 hourly 0.9 https://trial.medpath.com/zh/news/yale-surgeon-scientist-secures-fda-orphan-drug-designation-for-pembrolizumab-in-rare-respiratory-disease 2025-01-08T05:45:12+00:00 hourly 0.9 https://trial.medpath.com/news/hormone-replacement-therapy-and-cancer-survival-a-longitudinal-cohort-study 2025-01-08T05:32:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hormone-replacement-therapy-and-cancer-survival-a-longitudinal-cohort-study 2025-01-08T05:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-says-its-hpv-vaccine-for-men-was-approved 2025-01-08T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-says-its-hpv-vaccine-for-men-was-approved 2025-01-08T05:03:13+00:00 hourly 0.9 https://trial.medpath.com/news/corbus-pharmaceuticals-to-present-crb-701-clinical-data-at-asco-gu-2025 2025-01-08T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/corbus-pharmaceuticals-to-present-crb-701-clinical-data-at-asco-gu-2025 2025-01-08T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mifepristone-as-weekly-contraceptive-performs-beyond-expectations-in-b-clinical-trials-b 2025-01-08T04:18:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mifepristone-as-weekly-contraceptive-performs-beyond-expectations-in-b-clinical-trials-b 2025-01-08T04:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-q3-2024-earnings-highlight-clinical-progress-in-gene-therapy 2025-01-08T03:23:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-q3-2024-earnings-highlight-clinical-progress-in-gene-therapy 2025-01-08T03:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/galapagos-announces-strategic-split-and-restructured-gilead-partnership-in-major-corporate-overhaul 2025-01-08T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/galapagos-announces-strategic-split-and-restructured-gilead-partnership-in-major-corporate-overhaul 2025-01-08T03:14:00+00:00 hourly 0.9 https://trial.medpath.com/news/nicklaus-childrens-hospital-advances-pediatric-cancer-treatment-with-targeted-therapy 2025-01-08T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nicklaus-childrens-hospital-advances-pediatric-cancer-treatment-with-targeted-therapy 2025-01-08T03:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/arrowhead-pharmaceuticals-cfo-kenneth-myszkowski-sells-893095-in-stock 2025-01-08T02:29:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-cfo-kenneth-myszkowski-sells-893095-in-stock 2025-01-08T02:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-s-phase-iia-derma-data-in-cancer-b-patients-b-propels-its-stock-bioworld 2025-01-08T02:16:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-s-phase-iia-derma-data-in-cancer-b-patients-b-propels-its-stock-bioworld 2025-01-08T02:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-b-clinical-b-utility-of 2025-01-08T02:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/md-anderson-and-myriad-genetics-form-strategic-alliance-to-evaluate-b-clinical-b-utility-of 2025-01-08T02:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/advancing-immunotherapy-for-glioblastoma-duke-research-blog 2025-01-08T00:33:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancing-immunotherapy-for-glioblastoma-duke-research-blog 2025-01-08T00:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/6-of-seniors-depressed-adhd-and-hormones-novel-antipsychotic-eases-schizophrenia 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/6-of-seniors-depressed-adhd-and-hormones-novel-antipsychotic-eases-schizophrenia 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/modified-consent-procedures-may-enhance-psychedelic-trials-validity 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-consent-procedures-may-enhance-psychedelic-trials-validity 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-phase-1-2-clinical-trial-for-rec-4539-in-small-cell-lung-cancer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-phase-1-2-clinical-trial-for-rec-4539-in-small-cell-lung-cancer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthroughs-and-partnerships-in-medical-technology-and-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthroughs-and-partnerships-in-medical-technology-and-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-immunitybio-s-bladder-cancer-drug-after-second-review 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-immunitybio-s-bladder-cancer-drug-after-second-review 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ferring-s-gut-microbiome-drug-shows-promise-in-phase-3-trial-for-c-diff 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ferring-s-gut-microbiome-drug-shows-promise-in-phase-3-trial-for-c-diff 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/comparative-evaluation-of-high-flow-nasal-cannula-hfnc-vs-conventional-oxygen-therapy-cot-in-infants-after-non-cardiac-surgery 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/comparative-evaluation-of-high-flow-nasal-cannula-hfnc-vs-conventional-oxygen-therapy-cot-in-infants-after-non-cardiac-surgery 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-inovio-to-aim-immunotherapy-at-hard-to-treat-brain-tumour 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-and-inovio-to-aim-immunotherapy-at-hard-to-treat-brain-tumour 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/synairgen-advances-to-phase-3-trial-of-inhaled-covid-19-treatment-sng001 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synairgen-advances-to-phase-3-trial-of-inhaled-covid-19-treatment-sng001 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/modified-consent-procedures-may-enhance-psychedelic-drug-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/modified-consent-procedures-may-enhance-psychedelic-drug-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/trametinib-shows-breakthrough-results-in-children-with-severe-genetic-heart-condition 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/trametinib-shows-breakthrough-results-in-children-with-severe-genetic-heart-condition 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-4-month-tb-treatment-regimen-shows-effectiveness-comparable-to-standard-6-month-regimen 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-4-month-tb-treatment-regimen-shows-effectiveness-comparable-to-standard-6-month-regimen 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthroughs-in-non-small-cell-lung-cancer-research-highlight-new-treatment-pathways 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthroughs-in-non-small-cell-lung-cancer-research-highlight-new-treatment-pathways 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-decision-on-atara-biotherapeutics-tab-cel-expected-soon 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-decision-on-atara-biotherapeutics-tab-cel-expected-soon 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/biomarin-s-roctavian-receives-conditional-approval-in-europe-for-haemophilia-a-treatment 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biomarin-s-roctavian-receives-conditional-approval-in-europe-for-haemophilia-a-treatment 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/basilea-pharmaceutica-reports-progress-and-future-plans-for-its-r-d-portfolio 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/basilea-pharmaceutica-reports-progress-and-future-plans-for-its-r-d-portfolio 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/class-action-lawsuit-filed-against-bioage-labs-inc-following-discontinuation-of-azelaprag-trial 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/class-action-lawsuit-filed-against-bioage-labs-inc-following-discontinuation-of-azelaprag-trial 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/heart-device-impresses-fda-stryker-acquires-inari-medical 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/heart-device-impresses-fda-stryker-acquires-inari-medical 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alebund-pharmaceuticals-completes-series-c-financing-of-rmb-550-million 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alebund-pharmaceuticals-completes-series-c-financing-of-rmb-550-million 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/centessa-pharmaceuticals-appoints-stephen-kanes-md-phd-as-chief-medical-officer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/centessa-pharmaceuticals-appoints-stephen-kanes-md-phd-as-chief-medical-officer 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/jasper-therapeutics-announces-promising-results-from-beacon-study-for-briquilimab-in-chronic-spontaneous-urticaria 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jasper-therapeutics-announces-promising-results-from-beacon-study-for-briquilimab-in-chronic-spontaneous-urticaria 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hansa-biopharma-announces-key-developments-and-achievements-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hansa-biopharma-announces-key-developments-and-achievements-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-neurovive-s-traumatic-brain-injury-drug 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-neurovive-s-traumatic-brain-injury-drug 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/patient-reported-qol-outcomes-of-initial-cll-treatments-highlighted-at-ash-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/patient-reported-qol-outcomes-of-initial-cll-treatments-highlighted-at-ash-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uab-clinical-trials-offer-opportunities-for-participation-in-groundbreaking-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uab-clinical-trials-offer-opportunities-for-participation-in-groundbreaking-research 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-expands-ophthalmology-pipeline-with-regenxbio-gene-therapy-deal 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-expands-ophthalmology-pipeline-with-regenxbio-gene-therapy-deal 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/celgenes-multiple-myeloma-orphan-drug-gets-fda-approval 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/celgenes-multiple-myeloma-orphan-drug-gets-fda-approval 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-s-new-guidance-on-psychedelic-therapy-clinical-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-s-new-guidance-on-psychedelic-therapy-clinical-trials 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/avadel-reports-significant-growth-in-lumryz-sales-and-patient-adoption-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avadel-reports-significant-growth-in-lumryz-sales-and-patient-adoption-in-2024 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glp-1-receptor-agonists-linked-to-reduced-surgical-complications-in-diabetic-patients 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-linked-to-reduced-surgical-complications-in-diabetic-patients 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/shorla-oncology-announces-u-s-food-and-drug-administration-fda 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/shorla-oncology-announces-u-s-food-and-drug-administration-fda 2025-01-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/targeting-cd30-in-diffuse-large-b-cell-lymphoma-where-does-it-fit-in 2025-01-07T23:59:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/targeting-cd30-in-diffuse-large-b-cell-lymphoma-where-does-it-fit-in 2025-01-07T23:59:22+00:00 hourly 0.9 https://trial.medpath.com/news/solid-biosciences-revolutionary-dual-route-gene-therapy-for-friedreich-s-ataxia-gains 2025-01-07T23:47:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/solid-biosciences-revolutionary-dual-route-gene-therapy-for-friedreich-s-ataxia-gains 2025-01-07T23:47:58+00:00 hourly 0.9 https://trial.medpath.com/news/treating-brain-cancer-with-immunotherapy-stanford-medicine 2025-01-07T23:01:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treating-brain-cancer-with-immunotherapy-stanford-medicine 2025-01-07T23:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/b-precision-medicine-b-biotech-maze-therapeutics-files-for-a-100-million-ipo 2025-01-07T22:53:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/b-precision-medicine-b-biotech-maze-therapeutics-files-for-a-100-million-ipo 2025-01-07T22:53:02+00:00 hourly 0.9 https://trial.medpath.com/news/eoi-international-junior-gender-consultant-for-west-africa-ahgc 2025-01-07T21:39:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eoi-international-junior-gender-consultant-for-west-africa-ahgc 2025-01-07T21:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-new-guidance-on-sex-and-gender-considerations-in-medical-device-and-drug-development 2025-01-07T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-new-guidance-on-sex-and-gender-considerations-in-medical-device-and-drug-development 2025-01-07T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-therapeutics-swot-analysis-oncology-biotech-s-stock-faces-pivotal-year 2025-01-07T21:13:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-therapeutics-swot-analysis-oncology-biotech-s-stock-faces-pivotal-year 2025-01-07T21:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/a-single-center-single-arm-prospective-open-label-and-comparative-trial-to-evaluate-the-nature 2025-01-07T20:59:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-single-center-single-arm-prospective-open-label-and-comparative-trial-to-evaluate-the-nature 2025-01-07T20:59:56+00:00 hourly 0.9 https://trial.medpath.com/news/for-the-record-january-7-2025-dct-guidance-revised-short-form-policy-more 2025-01-07T20:58:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/for-the-record-january-7-2025-dct-guidance-revised-short-form-policy-more 2025-01-07T20:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/biopharma-layoffs-increase-by-3-in-2024-fierce-biotech-reports 2025-01-07T20:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/biopharma-layoffs-increase-by-3-in-2024-fierce-biotech-reports 2025-01-07T20:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/stereotactic-body-radiation-may-improve-survival-in-liver-cancer-subset 2025-01-07T20:19:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stereotactic-body-radiation-may-improve-survival-in-liver-cancer-subset 2025-01-07T20:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-to-develop-lenacapavir-and-hiv-testing-guidelines-managed-healthcare-executive 2025-01-07T20:07:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-to-develop-lenacapavir-and-hiv-testing-guidelines-managed-healthcare-executive 2025-01-07T20:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approvals-expand-initial-treatment-options-for-multiple-myeloma-national-cancer-institute 2025-01-07T18:50:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approvals-expand-initial-treatment-options-for-multiple-myeloma-national-cancer-institute 2025-01-07T18:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/prucalopride-tablets-for-chronic-idiopathic-constipation-b-launches-b-approved-for-180-day 2025-01-07T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prucalopride-tablets-for-chronic-idiopathic-constipation-b-launches-b-approved-for-180-day 2025-01-07T17:09:37+00:00 hourly 0.9 https://trial.medpath.com/news/myriad-genetics-md-anderson-forms-5-year-strategic-alliance 2025-01-07T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/myriad-genetics-md-anderson-forms-5-year-strategic-alliance 2025-01-07T17:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/wegovy-and-zepbound-tipped-to-fuel-20b-boom-in-heart-failure-market-fierce-pharma 2025-01-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wegovy-and-zepbound-tipped-to-fuel-20b-boom-in-heart-failure-market-fierce-pharma 2025-01-07T17:06:37+00:00 hourly 0.9 https://trial.medpath.com/news/francis-medical-secures-80m-series-c-funding-for-innovative-water-vapor-ablation-technology 2025-01-07T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/francis-medical-secures-80m-series-c-funding-for-innovative-water-vapor-ablation-technology 2025-01-07T16:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/dr-deangelo-on-the-b-fda-approval-b-of-blinatumomab-consolidation-in-cd19-ph-b-all 2025-01-07T15:34:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-deangelo-on-the-b-fda-approval-b-of-blinatumomab-consolidation-in-cd19-ph-b-all 2025-01-07T15:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/structure-therapeutics-earns-buy-rating-for-innovative-oral-obesity-treatments 2025-01-07T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/structure-therapeutics-earns-buy-rating-for-innovative-oral-obesity-treatments 2025-01-07T15:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-cns-gene-therapy-with-capsida-through-40-million-option 2025-01-07T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-advances-cns-gene-therapy-with-capsida-through-40-million-option 2025-01-07T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/jefferies-upgrades-instil-bio-highlighting-potential-of-syn2510-in-cancer-treatment 2025-01-07T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/jefferies-upgrades-instil-bio-highlighting-potential-of-syn2510-in-cancer-treatment 2025-01-07T14:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/avenzo-therapeutics-and-dualitybio-announce-exclusive-global-license-for-potential-best-in-class-egfr-her3-antibody-drug-conjugate 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/short-course-radiation-therapy-shows-promise-for-older-glioblastoma-patients 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/short-course-radiation-therapy-shows-promise-for-older-glioblastoma-patients 2025-01-07T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-greenlights-first-stem-cell-therapy-on-mixed-clinical-findings-citeline 2025-01-07T13:19:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-greenlights-first-stem-cell-therapy-on-mixed-clinical-findings-citeline 2025-01-07T13:19:41+00:00 hourly 0.9 https://trial.medpath.com/news/sling-therapeutics-appoints-andrew-guggenhime-to-its-board-of-directors 2025-01-07T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sling-therapeutics-appoints-andrew-guggenhime-to-its-board-of-directors 2025-01-07T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/marvel-biosciences-secures-funding-for-phase-1-clinical-trials-of-mb-204 2025-01-07T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marvel-biosciences-secures-funding-for-phase-1-clinical-trials-of-mb-204 2025-01-07T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/analyst-recommends-buying-arcturus-therapeutics-shares-due-to-h5n1-vaccine-demand 2025-01-07T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/analyst-recommends-buying-arcturus-therapeutics-shares-due-to-h5n1-vaccine-demand 2025-01-07T11:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/promising-phase-1-2-results-for-acelyrin-s-lonigutamab-support-buy-rating 2025-01-07T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-phase-1-2-results-for-acelyrin-s-lonigutamab-support-buy-rating 2025-01-07T11:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/xeltis-announces-completion-of-enrolment-in-eu-pivotal-trial-for-axess-and-prepares-for 2025-01-07T09:15:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xeltis-announces-completion-of-enrolment-in-eu-pivotal-trial-for-axess-and-prepares-for 2025-01-07T09:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/bial-announces-first-patient-out-in-its-phase-2-clinical-trial-of-bia-28-6156-biospace 2025-01-07T09:01:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bial-announces-first-patient-out-in-its-phase-2-clinical-trial-of-bia-28-6156-biospace 2025-01-07T09:01:28+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-studies-show-improved-survival-rates-in-pediatric-aml-transplantation 2025-01-07T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-studies-show-improved-survival-rates-in-pediatric-aml-transplantation 2025-01-07T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/precision-medicine-and-value-based-cancer-care-navigating-implementation-challenges-in-academic-and-community-settings 2025-01-07T08:50:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/precision-medicine-and-value-based-cancer-care-navigating-implementation-challenges-in-academic-and-community-settings 2025-01-07T08:50:38+00:00 hourly 0.9 https://trial.medpath.com/news/pacira-announces-fda-clearance-for-new-back-pain-treatment 2025-01-07T08:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pacira-announces-fda-clearance-for-new-back-pain-treatment 2025-01-07T08:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-publication-highlights-safety-and-potential-benefits-of-redosing-diamyd-r-precision 2025-01-07T08:08:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-publication-highlights-safety-and-potential-benefits-of-redosing-diamyd-r-precision 2025-01-07T08:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/qlife-provides-update-on-operational-progress-in-china-qlife-holding-ab-cision-news 2025-01-07T08:01:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qlife-provides-update-on-operational-progress-in-china-qlife-holding-ab-cision-news 2025-01-07T08:01:53+00:00 hourly 0.9 https://trial.medpath.com/news/qnovia-inc-announces-first-patient-dosed-in-u-s-phase-1-study-for-respirxtm-nicotine-inhaler 2025-01-07T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qnovia-inc-announces-first-patient-dosed-in-u-s-phase-1-study-for-respirxtm-nicotine-inhaler 2025-01-07T07:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/drug-pricing-reform-shows-promise-as-2000-medicare-out-of-pocket-cap-set-for-2025 2025-01-07T07:49:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/drug-pricing-reform-shows-promise-as-2000-medicare-out-of-pocket-cap-set-for-2025 2025-01-07T07:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/next-lifts-full-year-guidance-gsk-drug-gets-new-breakthrough-designation-sharecast-com 2025-01-07T07:36:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/next-lifts-full-year-guidance-gsk-drug-gets-new-breakthrough-designation-sharecast-com 2025-01-07T07:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/cormedix-inc-announces-preliminary-fourth-quarter-2024-results-and-provides-business-update 2025-01-07T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cormedix-inc-announces-preliminary-fourth-quarter-2024-results-and-provides-business-update 2025-01-07T07:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/opthea-reports-positive-phase-1b-dme-trial-results 2025-01-07T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opthea-reports-positive-phase-1b-dme-trial-results 2025-01-07T07:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/4sc-ag-4sc-announces-update-relating-to-resminostat-s-kinselby-marketing 2025-01-07T07:02:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/4sc-ag-4sc-announces-update-relating-to-resminostat-s-kinselby-marketing 2025-01-07T07:02:42+00:00 hourly 0.9 https://trial.medpath.com/news/evolution-of-managed-care-three-decades-of-healthcare-transformation-and-future-outlook 2025-01-07T07:00:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evolution-of-managed-care-three-decades-of-healthcare-transformation-and-future-outlook 2025-01-07T07:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/hope-therapeutics-to-acquire-kadima-neuropsychiatry-institute-as-flagship-for-global-interventional-psychiatry-network 2025-01-07T06:52:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-therapeutics-to-acquire-kadima-neuropsychiatry-institute-as-flagship-for-global-interventional-psychiatry-network 2025-01-07T06:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/global-dna-sequencing-market-set-to-reach-106-billion-by-2034-driven-by-next-generation-technologies 2025-01-07T06:47:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/global-dna-sequencing-market-set-to-reach-106-billion-by-2034-driven-by-next-generation-technologies 2025-01-07T06:47:33+00:00 hourly 0.9 https://trial.medpath.com/news/interius-biotherapeutics-expands-phase-1-clinical-trial-of-int2104-into-europe 2025-01-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/interius-biotherapeutics-expands-phase-1-clinical-trial-of-int2104-into-europe 2025-01-07T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alivegen-receives-fda-orphan-drug-designation-for-alg-801-for-pulmonary-arterial-hypertension 2025-01-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alivegen-receives-fda-orphan-drug-designation-for-alg-801-for-pulmonary-arterial-hypertension 2025-01-07T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/abl-bio-s-anticancer-drug-candidate-emerges-as-us-partner-s-core-pipeline-kbr 2025-01-07T04:22:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abl-bio-s-anticancer-drug-candidate-emerges-as-us-partner-s-core-pipeline-kbr 2025-01-07T04:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/vertex-partners-with-orna-in-700m-deal-to-develop-in-vivo-gene-therapies-for-blood-disorders 2025-01-07T04:19:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vertex-partners-with-orna-in-700m-deal-to-develop-in-vivo-gene-therapies-for-blood-disorders 2025-01-07T04:19:51+00:00 hourly 0.9 https://trial.medpath.com/news/cspc-pharmaceutical-s-syh2059-tablets-gain-clinical-trial-approval-in-china 2025-01-07T03:38:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cspc-pharmaceutical-s-syh2059-tablets-gain-clinical-trial-approval-in-china 2025-01-07T03:38:00+00:00 hourly 0.9 https://trial.medpath.com/news/candid-therapeutics-and-wuxi-biologics-forge-925m-deal-for-novel-t-cell-engager-development 2025-01-07T03:36:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/candid-therapeutics-and-wuxi-biologics-forge-925m-deal-for-novel-t-cell-engager-development 2025-01-07T03:36:37+00:00 hourly 0.9 https://trial.medpath.com/news/msd-acquires-wuxi-biologics-irish-vaccine-facility-for-500m-amid-regulatory-pressures 2025-01-07T03:10:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/msd-acquires-wuxi-biologics-irish-vaccine-facility-for-500m-amid-regulatory-pressures 2025-01-07T03:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for 2025-01-07T01:12:46+00:00 hourly 0.9 https://trial.medpath.com/zh/news/norgine-submits-marketing-authorisation-application-to-the-european-medicines-agency-for 2025-01-07T01:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/cell-gene-therapies-pink-sheet-citeline 2025-01-07T01:09:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cell-gene-therapies-pink-sheet-citeline 2025-01-07T01:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/the-registrational-clinical-data-of-glecirasib-was-published-in-nature-medicine 2025-01-07T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-registrational-clinical-data-of-glecirasib-was-published-in-nature-medicine 2025-01-07T00:48:13+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-expands-gene-therapy-portfolio-with-decibel-therapeutics-acquisition 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-expands-gene-therapy-portfolio-with-decibel-therapeutics-acquisition 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-to-test-copd-hopeful-ensifentrine-in-covid-19-patients 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-scores-adjuvant-lung-cancer-approval-for-tecentriq 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-scores-adjuvant-lung-cancer-approval-for-tecentriq 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hoth-therapeutics-achieves-breakthrough-in-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/odronextamab-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/odronextamab-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rapt-therapeutics-announces-initiation-of-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rapt-therapeutics-announces-initiation-of-phase-2a-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-ii-trial-shows-ambroxol-safe-but-ineffective-for-parkinson-s-disease-dementia-cognitive-symptoms 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-ii-trial-shows-ambroxol-safe-but-ineffective-for-parkinson-s-disease-dementia-cognitive-symptoms 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-app-could-revolutionise-ophthalmic-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-app-could-revolutionise-ophthalmic-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eu-approves-enhertu-for-her2-low-breast-cancer-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eu-approves-enhertu-for-her2-low-breast-cancer-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-clears-ai-that-detects-heart-failure-using-a-stethoscope 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-clears-ai-that-detects-heart-failure-using-a-stethoscope 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-congenital-hyperinsulinism 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dimerix-has-entered-into-a-development-and-license-agreement-for-japan 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dimerix-has-entered-into-a-development-and-license-agreement-for-japan 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sarepta-files-duchenne-muscular-dystrophy-gene-therapy-with-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sarepta-files-duchenne-muscular-dystrophy-gene-therapy-with-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-advisers-reject-new-use-for-pacira-nerve-block 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-advisers-reject-new-use-for-pacira-nerve-block 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/homozygous-familial-hypercholesterolemia-treatment-market-to-surge-by-2034 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/homozygous-familial-hypercholesterolemia-treatment-market-to-surge-by-2034 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eqs-news-immunic-highlights-2024-accomplishments-and 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eqs-news-immunic-highlights-2024-accomplishments-and 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/google-s-anti-aging-company-just-released-disappointing 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pmv-pharmaceuticals-inc-pmvp 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pmv-pharmaceuticals-inc-pmvp 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/january-7-2025-after-tough-year-moderna-ceo-confronts 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/january-7-2025-after-tough-year-moderna-ceo-confronts 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-industry-surges-to-141-2-billion-in-funding-as-clinical-success-drives-investment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-industry-surges-to-141-2-billion-in-funding-as-clinical-success-drives-investment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/aldeyras-reproxalap-for-dry-eye-disease-accepted-by-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/aldeyras-reproxalap-for-dry-eye-disease-accepted-by-fda 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tyra-biosciences-reports-third-quarter-2024-financial-results-and-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-trial-win-sets-up-rare-disease-drug-filing-for-csl 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-trial-win-sets-up-rare-disease-drug-filing-for-csl 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-and-astrazeneca-highlight-tezspire-s-potential-in-copd-treatment-despite-trial-outcome 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-and-astrazeneca-highlight-tezspire-s-potential-in-copd-treatment-despite-trial-outcome 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-s-haemophilia-b-gene-therapy-meets-phase-3-primary-endpoint 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-s-haemophilia-b-gene-therapy-meets-phase-3-primary-endpoint 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/news-for-the-cardiac-and-vascular-medtech-and-biotech 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/news-for-the-cardiac-and-vascular-medtech-and-biotech 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-fda-approves-aop-health-s-rapiblyktm-landiolol-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-fda-approves-aop-health-s-rapiblyktm-landiolol-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-heart-failure-use-for-az-s-farxiga 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-heart-failure-use-for-az-s-farxiga 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bofa-cuts-denali-therapeutics-stock-target-as-als-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bofa-cuts-denali-therapeutics-stock-target-as-als-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-pharmaceuticals-inc-rxrx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-pharmaceuticals-inc-rxrx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mammaprint-assay-identifies-subgroup-benefiting-from-extended-letrozole-therapy-in-early-stage-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mammaprint-assay-identifies-subgroup-benefiting-from-extended-letrozole-therapy-in-early-stage-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/halda-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/halda-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/onl-therapeutics-strengthens-leadership-with-appointment-of-penny-fleck-as-chief-development-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/onl-therapeutics-strengthens-leadership-with-appointment-of-penny-fleck-as-chief-development-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/neurotech-fda-update-on-nt-501-mactel-treatment-obn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurotech-fda-update-on-nt-501-mactel-treatment-obn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regenxbio-expands-mps-i-gene-therapy-trial-after-initial-data-review 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regenxbio-expands-mps-i-gene-therapy-trial-after-initial-data-review 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immuneering-reports-positive-phase-2a-data-for-imm-1-104 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immuneering-reports-positive-phase-2a-data-for-imm-1-104 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/az-s-antibody-first-to-be-cleared-by-fda-for-covid-prevention 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/az-s-antibody-first-to-be-cleared-by-fda-for-covid-prevention 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tesaro-s-niraparib-approved-in-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tesaro-s-niraparib-approved-in-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advances-in-nephrology-breakthroughs-in-kidney-transplantation-and-disease-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advances-in-nephrology-breakthroughs-in-kidney-transplantation-and-disease-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bright-minds-biosciences-appoints-stephen-collins-m-d-ph-d-as-chief-medical-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bright-minds-biosciences-appoints-stephen-collins-m-d-ph-d-as-chief-medical-officer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/could-crispr-cure-hiv-us-biotech-excision-raises-60m-to-find-out 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/could-crispr-cure-hiv-us-biotech-excision-raises-60m-to-find-out 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/us-fda-accepts-nda-filing-for-bi-s-nintedanib 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/us-fda-accepts-nda-filing-for-bi-s-nintedanib 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-looks-to-digitise-drug-trials-with-koneksa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-looks-to-digitise-drug-trials-with-koneksa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-wild-card-drug-scemblix-gets-fda-nod-for-leukaemia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/iterum-therapeutics-nasdaq-itrm-stock-quotes-forecast-and-news-summary 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iterum-therapeutics-nasdaq-itrm-stock-quotes-forecast-and-news-summary 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/som-s-ai-discovered-drug-shows-promise-in-huntington-s-disease 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/som-s-ai-discovered-drug-shows-promise-in-huntington-s-disease 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-bayer-merck-co-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-bayer-merck-co-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-bans-use-of-lilly-regeneron-covid-drugs-due-to-omicron 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-points-to-weaknesses-in-fda-accelerated-approval-path 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-points-to-weaknesses-in-fda-accelerated-approval-path 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/single-dose-hpv-vaccine-shows-promise-in-long-term-cervical-cancer-prevention-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/single-dose-hpv-vaccine-shows-promise-in-long-term-cervical-cancer-prevention-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-gives-abbvie-s-c-met-lung-cancer-adc-a-breakthrough-tag 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-gives-abbvie-s-c-met-lung-cancer-adc-a-breakthrough-tag 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/how-effective-are-glp-1-meds-for-weight-loss-in-people-without-diabetes 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/how-effective-are-glp-1-meds-for-weight-loss-in-people-without-diabetes 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/actuate-therapeutics-receives-ema-orphan-medicinal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/actuate-therapeutics-receives-ema-orphan-medicinal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cassava-sciences-provides-a-business-update 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cassava-sciences-provides-a-business-update 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthrough-in-xenotransplantation-genetically-engineered-pig-hearts-show-promise-for-human-transplantation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthrough-in-xenotransplantation-genetically-engineered-pig-hearts-show-promise-for-human-transplantation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-cytokinetics-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-cytokinetics-heart-failure-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-sets-november-review-date-for-j-j-s-multiple-myeloma-car-t-cilta-cel 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-sets-november-review-date-for-j-j-s-multiple-myeloma-car-t-cilta-cel 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-chalks-hidradenitis-suppurativa-as-fifth-indication-for-bimzelx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-chalks-hidradenitis-suppurativa-as-fifth-indication-for-bimzelx 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nippon-shinyakus-dmd-drug-fails-confirmatory-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nippon-shinyakus-dmd-drug-fails-confirmatory-trial 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/metseras-touts-powerful-weight-loss-results-again 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/metseras-touts-powerful-weight-loss-results-again 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-emrosi-for-rosacea-in-adults-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-emrosi-for-rosacea-in-adults-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/agios-up-as-fda-gives-thermo-fisher-glioma-test-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/agios-up-as-fda-gives-thermo-fisher-glioma-test-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/second-time-lucky-at-fda-for-citius-lymphoma-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-time-lucky-at-fda-for-citius-lymphoma-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verona-pharma-reports-strong-ohtuvayretm-launch-and-provides-preliminary-fourth-quarter-and-full-year-2024-financial-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verona-pharma-reports-strong-ohtuvayretm-launch-and-provides-preliminary-fourth-quarter-and-full-year-2024-financial-highlights 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/press-release-six-month-data-from-alfapump-r-pivotal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/press-release-six-month-data-from-alfapump-r-pivotal 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immunogen-elahere-wins-accelerated-fda-approval-for-ovarian-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainchild-bio-inc-to-clinically-advance-bcb-276-an 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/egg-maturation-supported-by-stem-cells-results-in-first-live 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/egg-maturation-supported-by-stem-cells-results-in-first-live 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-updates-on-avicursen-primate-toxicology-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-updates-on-avicursen-primate-toxicology-study 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/rsv-vaccines-add-guillain-barre-warning-conexiant 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rsv-vaccines-add-guillain-barre-warning-conexiant 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novartis-taps-immuno-oncology-partner-beigene-for-tigit-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vyloy-zolbetuximab-uses-dosage-side-effects-warnings-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyloy-zolbetuximab-uses-dosage-side-effects-warnings-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/govorestat-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/govorestat-what-is-it-and-is-it-fda-approved-drugs-com 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lin-bioscience-inc-lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lin-bioscience-inc-lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/geron-corporation-gern-stock-price-news-quote-history-yahoo-finance 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/geron-corporation-gern-stock-price-news-quote-history-yahoo-finance 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/inside-esmo-2024-treatments-trials-and-top-hcps-on-social-media 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inside-esmo-2024-treatments-trials-and-top-hcps-on-social-media 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-scores-adjuvant-lung-cancer-approval-for-tecentriq 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-scores-adjuvant-lung-cancer-approval-for-tecentriq 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fire1-raises-120m-to-develop-its-heart-failure 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fire1-raises-120m-to-develop-its-heart-failure 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-looks-at-pulling-speedy-approvals-for-three-cancer-drugs 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizers-rsv-shot-clears-fda-adcomm-now-its-gsks-turn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizers-rsv-shot-clears-fda-adcomm-now-its-gsks-turn 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-fast-tracks-gsks-chronic-hep-b-therapy-bepirovirsen 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-fast-tracks-gsks-chronic-hep-b-therapy-bepirovirsen 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/beyond-covid-19-mrna-vaccines-aim-to-revolutionise-cancer-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/beyond-covid-19-mrna-vaccines-aim-to-revolutionise-cancer-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eisai-co-ltd-advances-in-narcolepsy-and-alzheimer-s-disease-treatments 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/johnson-johnson-medtech-temporarily-pauses-u-s-varipulse-cases 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/johnson-johnson-medtech-temporarily-pauses-u-s-varipulse-cases 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/camurus-provides-regulatory-update-on-the-us-nda-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/camurus-provides-regulatory-update-on-the-us-nda-for 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lundbeck-and-takeda-seek-fda-approval-for-antidepressant-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lundbeck-and-takeda-seek-fda-approval-for-antidepressant-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/carrots-show-potential-in-diabetes-treatment-through-gut-microbiome-alteration 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/carrots-show-potential-in-diabetes-treatment-through-gut-microbiome-alteration 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tune-therapeutics-receives-approval-to-initiate-clinical 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tune-therapeutics-receives-approval-to-initiate-clinical 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/recursion-announces-two-key-investigational-oncology 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/recursion-announces-two-key-investigational-oncology 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthroughs-and-challenges-in-gene-therapy-a-2024-overview 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthroughs-and-challenges-in-gene-therapy-a-2024-overview 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vergent-bioscience-receives-fda-fast-track-designation 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-says-lung-cancer-combo-improves-survival-more-than-standard-of-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-says-lung-cancer-combo-improves-survival-more-than-standard-of-care 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bicycle-therapeutics-partners-with-cancer-research-uk-for-cancer-treatment-development 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bicycle-therapeutics-partners-with-cancer-research-uk-for-cancer-treatment-development 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/baxter-alzheimers-drug-fails-to-meet-phase-3-endpoints 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/baxter-alzheimers-drug-fails-to-meet-phase-3-endpoints 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-tx-craters-as-fda-rejects-lead-product-candidate 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-tx-craters-as-fda-rejects-lead-product-candidate 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-gives-pfizer-s-group-b-strep-vaccine-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-gives-pfizer-s-group-b-strep-vaccine-breakthrough-status 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/maia-biotechnology-inc-maia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/maia-biotechnology-inc-maia 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/akero-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/akero-therapeutics-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/luspatercept-lenalidomide-combo-demonstrates-safety 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/luspatercept-lenalidomide-combo-demonstrates-safety 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-roundup-january-7-2025 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-roundup-january-7-2025 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-btk-degrader-nx-5948-yields-high-response 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-btk-degrader-nx-5948-yields-high-response 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-industry-surges-to-141-2-billion-in-funding-as-clinical-success-drives-investment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-industry-surges-to-141-2-billion-in-funding-as-clinical-success-drives-investment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/verismo-therapeutics-announces-strategic-partnership 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alleviant-medical-wins-fda-ide-breakthrough-nods-for-no-implant-heart-failure-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alleviant-medical-wins-fda-ide-breakthrough-nods-for-no-implant-heart-failure-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-turns-down-satsumas-nasal-migraine-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-turns-down-satsumas-nasal-migraine-treatment 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-rejects-ucb-s-psoriasis-therapy-bimekizumab 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/accurkardia-receives-fda-breakthrough-device-designation-for-ai-powered-hyperkalemia-detection-solution-using-lead-i-ecg-data 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accurkardia-receives-fda-breakthrough-device-designation-for-ai-powered-hyperkalemia-detection-solution-using-lead-i-ecg-data 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/regeneron-and-lilly-post-new-data-backing-covid-antibody-cocktails 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/regeneron-and-lilly-post-new-data-backing-covid-antibody-cocktails 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/u-s-fda-granted-priority-review-to-dizal-s-sunvozertinib-new-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/u-s-fda-granted-priority-review-to-dizal-s-sunvozertinib-new-drug 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/raphael-pharmaceutical-announces-positive-proof-of 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/raphael-pharmaceutical-announces-positive-proof-of 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/restem-receives-fda-fast-track-designation-for-restem-l-for-idiopathic-inflammatory-myopathy 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/senseera-raises-7-1-million-seed-round-led-by 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senseera-raises-7-1-million-seed-round-led-by 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/simpson-interventions-announces-both-ide-approval-from 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reveals-diversity-action-plan-guide-for-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reveals-diversity-action-plan-guide-for-clinical-trials 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-third-indication-requested-in-china-for-nubeqa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-third-indication-requested-in-china-for-nubeqa 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gsk-s-parp-drug-zejula-approved-in-wider-ovarian-cancer-population 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gsk-s-parp-drug-zejula-approved-in-wider-ovarian-cancer-population 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-priority-review-of-astellas-zolbetuximab-bla 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-priority-review-of-astellas-zolbetuximab-bla 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/alkeus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/alkeus-pharmaceuticals-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-removes-leash-from-verzenio-in-early-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-removes-leash-from-verzenio-in-early-breast-cancer 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/summit-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/summit-therapeutics-to-present-at-the-43rd-annual-j-p 2025-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/clinical-trial-protocol-deviations-a-new-fda-draft-guidance-to-ring-in-the-new-year 2025-01-06T22:53:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/clinical-trial-protocol-deviations-a-new-fda-draft-guidance-to-ring-in-the-new-year 2025-01-06T22:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/poly-adp-ribose-polymerase-parp-inhibitor-regimens-for-platinum-sensitive-ovarian-frontiers 2025-01-06T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/poly-adp-ribose-polymerase-parp-inhibitor-regimens-for-platinum-sensitive-ovarian-frontiers 2025-01-06T22:31:59+00:00 hourly 0.9 https://trial.medpath.com/news/with-phase-iii-success-pharmaessentia-to-seek-besremi-label-expansion 2025-01-06T22:28:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/with-phase-iii-success-pharmaessentia-to-seek-besremi-label-expansion 2025-01-06T22:28:19+00:00 hourly 0.9 https://trial.medpath.com/news/accelerated-approval-us-fda-explains-when-a-confirmatory-trial-is-underway 2025-01-06T22:19:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/accelerated-approval-us-fda-explains-when-a-confirmatory-trial-is-underway 2025-01-06T22:19:04+00:00 hourly 0.9 https://trial.medpath.com/news/cytomx-therapeutics-announces-2025-strategic-pipeline-priorities-and-provides-corporate-update 2025-01-06T22:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomx-therapeutics-announces-2025-strategic-pipeline-priorities-and-provides-corporate-update 2025-01-06T22:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/denali-therapeutics-als-drug-trial-falls-short-as-dnl343-misses-primary-endpoint 2025-01-06T21:34:37+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denali-therapeutics-als-drug-trial-falls-short-as-dnl343-misses-primary-endpoint 2025-01-06T21:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/updated-acelyrin-s-stock-drops-due-to-mixed-phase-2-data 2025-01-06T21:30:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/updated-acelyrin-s-stock-drops-due-to-mixed-phase-2-data 2025-01-06T21:30:23+00:00 hourly 0.9 https://trial.medpath.com/news/stimulating-fat-cells-with-gip-receptor-has-potential-to-treat-obesity 2025-01-06T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stimulating-fat-cells-with-gip-receptor-has-potential-to-treat-obesity 2025-01-06T21:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/upamostat-combo-demonstrates-tolerability-in-metastatic-pancreatic-cancer 2025-01-06T21:27:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/upamostat-combo-demonstrates-tolerability-in-metastatic-pancreatic-cancer 2025-01-06T21:27:32+00:00 hourly 0.9 https://trial.medpath.com/news/arcturus-therapeutics-announces-initiation-of-dosing-in-phase-2-multiple-ascending-morningstar 2025-01-06T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/arcturus-therapeutics-announces-initiation-of-dosing-in-phase-2-multiple-ascending-morningstar 2025-01-06T21:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/mrd-status-prior-to-allo-hsct-shows-strong-prognostic-value-in-aml-mds 2025-01-06T21:09:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mrd-status-prior-to-allo-hsct-shows-strong-prognostic-value-in-aml-mds 2025-01-06T21:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/medtronic-s-harmony-tpvr-system-gains-ce-mark-approval-cardiovascular-business 2025-01-06T20:23:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/medtronic-s-harmony-tpvr-system-gains-ce-mark-approval-cardiovascular-business 2025-01-06T20:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/sti-prevention-method-shows-promise-in-curbing-infections-in-groups-at-high-risk 2025-01-06T20:14:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sti-prevention-method-shows-promise-in-curbing-infections-in-groups-at-high-risk 2025-01-06T20:14:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-star-therapeutics-vga039-for-von-willebrand-disease 2025-01-06T19:51:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-star-therapeutics-vga039-for-von-willebrand-disease 2025-01-06T19:51:09+00:00 hourly 0.9 https://trial.medpath.com/news/second-line-axi-cel-is-efficacious-safe-in-real-world-patients-with-r-r-lbcl-onclive 2025-01-06T19:22:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/second-line-axi-cel-is-efficacious-safe-in-real-world-patients-with-r-r-lbcl-onclive 2025-01-06T19:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/study-confirms-ct-p42-therapeutic-equivalence-to-reference-aflibercept-in-dme 2025-01-06T19:16:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-confirms-ct-p42-therapeutic-equivalence-to-reference-aflibercept-in-dme 2025-01-06T19:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/dr-levee-on-immune-related-aes-associated-with-icis-in-early-breast-cancer-onclive 2025-01-06T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dr-levee-on-immune-related-aes-associated-with-icis-in-early-breast-cancer-onclive 2025-01-06T19:07:23+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaessentia-announces-positive-topline-phase-3-data-from-surpass-et-study-biospace 2025-01-06T19:04:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaessentia-announces-positive-topline-phase-3-data-from-surpass-et-study-biospace 2025-01-06T19:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-draft-guidance-on-including-tissue-biopsies-in-clinical-trials-biospace 2025-01-06T19:04:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-on-including-tissue-biopsies-in-clinical-trials-biospace 2025-01-06T19:04:22+00:00 hourly 0.9 https://trial.medpath.com/news/cms-issues-permanent-reimbursement-code-for-anktiva-urology-times 2025-01-06T19:00:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cms-issues-permanent-reimbursement-code-for-anktiva-urology-times 2025-01-06T19:00:31+00:00 hourly 0.9 https://trial.medpath.com/news/viking-therapeutics-and-structure-therapeutics-seen-as-key-partners-in-weight-loss-market 2025-01-06T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/viking-therapeutics-and-structure-therapeutics-seen-as-key-partners-in-weight-loss-market 2025-01-06T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/abbott-india-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-ursodeoxycholic-acid-tablet 2025-01-06T18:49:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbott-india-gets-cdsco-panel-nod-to-conduct-phase-iii-ct-of-ursodeoxycholic-acid-tablet 2025-01-06T18:49:47+00:00 hourly 0.9 https://trial.medpath.com/news/relativity-047-extended-analysis-of-overall-survival-with-nivolumab-relatlimab-vs 2025-01-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/relativity-047-extended-analysis-of-overall-survival-with-nivolumab-relatlimab-vs 2025-01-06T18:10:43+00:00 hourly 0.9 https://trial.medpath.com/news/impact-of-non-abl1-mutations-on-outcomes-in-chronic-myeloid-leukemia 2025-01-06T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/impact-of-non-abl1-mutations-on-outcomes-in-chronic-myeloid-leukemia 2025-01-06T18:08:09+00:00 hourly 0.9 https://trial.medpath.com/news/dose-escalation-completed-for-rise-therapeutics-r-3750-and-r-2487-clinical-trials 2025-01-06T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dose-escalation-completed-for-rise-therapeutics-r-3750-and-r-2487-clinical-trials 2025-01-06T17:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/dog-aging-project-receives-7-million-nih-grant-to-expand-clinical-trial-of-anti-aging-drug 2025-01-06T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dog-aging-project-receives-7-million-nih-grant-to-expand-clinical-trial-of-anti-aging-drug 2025-01-06T17:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/inmune-bio-s-treatment-for-epidermolysis-bullosa-awarded-fda-orphan-designation 2025-01-06T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/inmune-bio-s-treatment-for-epidermolysis-bullosa-awarded-fda-orphan-designation 2025-01-06T17:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/crispr-repairs-limb-girdle-muscular-dystrophy-2b-mutation-and-phenotypes-in-patient 2025-01-06T16:44:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/crispr-repairs-limb-girdle-muscular-dystrophy-2b-mutation-and-phenotypes-in-patient 2025-01-06T16:44:10+00:00 hourly 0.9 https://trial.medpath.com/news/insight-003-trial-of-eftilagimod-alpha-combo-in-nsclc-completes-enrollment 2025-01-06T16:38:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insight-003-trial-of-eftilagimod-alpha-combo-in-nsclc-completes-enrollment 2025-01-06T16:38:35+00:00 hourly 0.9 https://trial.medpath.com/news/tarlatamab-earns-uk-approval-for-previously-treated-es-sclc-onclive 2025-01-06T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tarlatamab-earns-uk-approval-for-previously-treated-es-sclc-onclive 2025-01-06T16:38:10+00:00 hourly 0.9 https://trial.medpath.com/news/nanovibronix-completes-pilot-phase-of-us-trial-with-uroshield 2025-01-06T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nanovibronix-completes-pilot-phase-of-us-trial-with-uroshield 2025-01-06T16:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-chemotherapy-antidote-could-improve-recovery-after-mass-general-brigham 2025-01-06T16:13:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-chemotherapy-antidote-could-improve-recovery-after-mass-general-brigham 2025-01-06T16:13:25+00:00 hourly 0.9 https://trial.medpath.com/news/castle-biosciences-gains-new-york-state-approval-for-barrett-s-oesophagus-test 2025-01-06T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/zh/news/castle-biosciences-gains-new-york-state-approval-for-barrett-s-oesophagus-test 2025-01-06T16:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/sean-m-healey-amg-center-announces-update-in-als-platform-trial-with-fosigotifator 2025-01-06T16:00:47+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sean-m-healey-amg-center-announces-update-in-als-platform-trial-with-fosigotifator 2025-01-06T16:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/veliparib-and-temozolomide-combo-does-not-significantly-extend-survival-for-patients-with-glioma 2025-01-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/veliparib-and-temozolomide-combo-does-not-significantly-extend-survival-for-patients-with-glioma 2025-01-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/10-clinical-trials-of-2024-hits-misses-and-some-in-between-citeline-news-insights 2025-01-06T15:42:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/10-clinical-trials-of-2024-hits-misses-and-some-in-between-citeline-news-insights 2025-01-06T15:42:34+00:00 hourly 0.9 https://trial.medpath.com/news/adverse-events-of-hepatic-anti-fibrotic-agents-in-phase-3-and-above-clinical-trials-frontiers 2025-01-06T15:31:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adverse-events-of-hepatic-anti-fibrotic-agents-in-phase-3-and-above-clinical-trials-frontiers 2025-01-06T15:31:27+00:00 hourly 0.9 https://trial.medpath.com/news/serina-therapeutics-advances-parkinson-s-treatment-with-ser-252-clinical-trials-set-for-2025 2025-01-06T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/serina-therapeutics-advances-parkinson-s-treatment-with-ser-252-clinical-trials-set-for-2025 2025-01-06T15:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/woman-cancer-free-after-uk-s-first-liver-transplant-for-advanced-bowel-cancer 2025-01-06T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/woman-cancer-free-after-uk-s-first-liver-transplant-for-advanced-bowel-cancer 2025-01-06T15:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/atopic-dermatitis-clinical-trials-2024-a-comprehensive-overview 2025-01-06T15:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/atopic-dermatitis-clinical-trials-2024-a-comprehensive-overview 2025-01-06T15:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/imetelstat-plus-ruxolitinib-demonstrates-tolerable-safety-profile-in-myelofibrosis-onclive 2025-01-06T15:08:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/imetelstat-plus-ruxolitinib-demonstrates-tolerable-safety-profile-in-myelofibrosis-onclive 2025-01-06T15:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/caribou-biosciences-price-target-increased-by-brookline 2025-01-06T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/caribou-biosciences-price-target-increased-by-brookline 2025-01-06T14:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/eli-lilly-seeks-to-join-lawsuit-on-compounded-drugs-stat-news 2025-01-06T14:41:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eli-lilly-seeks-to-join-lawsuit-on-compounded-drugs-stat-news 2025-01-06T14:41:08+00:00 hourly 0.9 https://trial.medpath.com/news/esophageal-cancer-market-report-2034-epidemiology-pipeline-therapies-and-latest-approvals 2025-01-06T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/esophageal-cancer-market-report-2034-epidemiology-pipeline-therapies-and-latest-approvals 2025-01-06T14:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/amylyx-pharmaceuticals-appoints-dan-monahan-as-chief-commercial-officer-morningstar 2025-01-06T14:16:26+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amylyx-pharmaceuticals-appoints-dan-monahan-as-chief-commercial-officer-morningstar 2025-01-06T14:16:26+00:00 hourly 0.9 https://trial.medpath.com/news/neurosense-regains-compliance-with-nasdaq-s-minimum-equity-requirement-stock-titan 2025-01-06T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/neurosense-regains-compliance-with-nasdaq-s-minimum-equity-requirement-stock-titan 2025-01-06T14:14:06+00:00 hourly 0.9 https://trial.medpath.com/news/anito-cel-demonstrates-safety-and-early-efficacy-in-r-r-multiple-myeloma-onclive 2025-01-06T14:07:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/anito-cel-demonstrates-safety-and-early-efficacy-in-r-r-multiple-myeloma-onclive 2025-01-06T14:07:54+00:00 hourly 0.9 https://trial.medpath.com/news/investigators-hope-for-potential-breakthrough-in-dual-cellular-therapy-approach-for 2025-01-06T13:58:13+00:00 hourly 0.9 https://trial.medpath.com/zh/news/investigators-hope-for-potential-breakthrough-in-dual-cellular-therapy-approach-for 2025-01-06T13:58:13+00:00 hourly 0.9 https://trial.medpath.com/news/quoin-s-netherton-syndrome-treatment-shows-dramatic-83-symptom-reduction-in-clinical-trial 2025-01-06T13:36:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/quoin-s-netherton-syndrome-treatment-shows-dramatic-83-symptom-reduction-in-clinical-trial 2025-01-06T13:36:11+00:00 hourly 0.9 https://trial.medpath.com/news/organovo-announces-appointment-of-norman-staskey-as-chief-financial-officer 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/organovo-announces-appointment-of-norman-staskey-as-chief-financial-officer 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/nocira-r-grows-patent-portfolio-for-personalized-adaptive-migraine-treatments 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nocira-r-grows-patent-portfolio-for-personalized-adaptive-migraine-treatments 2025-01-06T13:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/unity-biotech-appoints-syfovre-developer-dr-grossi-as-cmo-ahead-of-key-dme-trial 2025-01-06T13:25:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unity-biotech-appoints-syfovre-developer-dr-grossi-as-cmo-ahead-of-key-dme-trial 2025-01-06T13:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/spectral-medical-provides-december-tigris-trial-update-financial-post 2025-01-06T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/spectral-medical-provides-december-tigris-trial-update-financial-post 2025-01-06T13:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/casi-pharmaceuticals-launches-pivotal-phase-1-2-trial-for-novel-itp-treatment-cid-103 2025-01-06T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/casi-pharmaceuticals-launches-pivotal-phase-1-2-trial-for-novel-itp-treatment-cid-103 2025-01-06T13:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/fda-reviews-cutx-101-for-menkes-disease-treatment-investing-com 2025-01-06T13:15:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-reviews-cutx-101-for-menkes-disease-treatment-investing-com 2025-01-06T13:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/stroke-care-device-maker-wellumio-expands-u-s-footprint-massdevice 2025-01-06T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stroke-care-device-maker-wellumio-expands-u-s-footprint-massdevice 2025-01-06T13:03:31+00:00 hourly 0.9 https://trial.medpath.com/news/iparomlimab-tuvonralimab-plus-chemo-bevacizumab-yields-responses-in-recurrent-onclive 2025-01-06T13:02:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/iparomlimab-tuvonralimab-plus-chemo-bevacizumab-yields-responses-in-recurrent-onclive 2025-01-06T13:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/extended-paxlovid-may-help-some-people-with-long-covid-uc-san-francisco 2025-01-06T13:01:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/extended-paxlovid-may-help-some-people-with-long-covid-uc-san-francisco 2025-01-06T13:01:43+00:00 hourly 0.9 https://trial.medpath.com/news/lineage-cell-therapeutics-updates-shareholders-on-progress-and-2025-outlook 2025-01-06T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lineage-cell-therapeutics-updates-shareholders-on-progress-and-2025-outlook 2025-01-06T13:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/unity-biotechnology-prepares-for-key-data-readouts-in-2025-for-ubx1325-in-diabetic 2025-01-06T12:46:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/unity-biotechnology-prepares-for-key-data-readouts-in-2025-for-ubx1325-in-diabetic 2025-01-06T12:46:31+00:00 hourly 0.9 https://trial.medpath.com/news/vyne-therapeutics-completes-phase-2b-trial-enrollment-for-novel-vitiligo-treatment-vyn201 2025-01-06T12:36:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/vyne-therapeutics-completes-phase-2b-trial-enrollment-for-novel-vitiligo-treatment-vyn201 2025-01-06T12:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/xortx-launches-xrx-026-program-for-allopurinol-intolerant-gout-patients-targets-fda-approval 2025-01-06T12:19:07+00:00 hourly 0.9 https://trial.medpath.com/zh/news/xortx-launches-xrx-026-program-for-allopurinol-intolerant-gout-patients-targets-fda-approval 2025-01-06T12:19:07+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-therapeutics-signs-business-research-globenewswire 2025-01-06T12:05:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomed-therapeutics-signs-business-research-globenewswire 2025-01-06T12:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/essex-bio-technology-completes-phase-3-study-for-wet-amd-treatment-markets-insider 2025-01-06T11:52:48+00:00 hourly 0.9 https://trial.medpath.com/zh/news/essex-bio-technology-completes-phase-3-study-for-wet-amd-treatment-markets-insider 2025-01-06T11:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/uk-conditionally-approves-amgen-s-drug-for-aggressive-lung-cancer-in-pretreated-patients 2025-01-06T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-conditionally-approves-amgen-s-drug-for-aggressive-lung-cancer-in-pretreated-patients 2025-01-06T11:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/nasdaq-grants-revelation-biosciences-inc-continued-listing-stock-titan 2025-01-06T11:17:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nasdaq-grants-revelation-biosciences-inc-continued-listing-stock-titan 2025-01-06T11:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/glecirasib-in-kras-g12c-mutated-nonsmall-cell-lung-cancer-a-phase-2b-trial-nature 2025-01-06T11:13:53+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glecirasib-in-kras-g12c-mutated-nonsmall-cell-lung-cancer-a-phase-2b-trial-nature 2025-01-06T11:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/selumetinib-in-adults-with-nf1-and-inoperable-plexiform-neurofibroma-a-phase-2-trial 2025-01-06T11:13:44+00:00 hourly 0.9 https://trial.medpath.com/zh/news/selumetinib-in-adults-with-nf1-and-inoperable-plexiform-neurofibroma-a-phase-2-trial 2025-01-06T11:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/prediction-of-checkpoint-inhibitor-immunotherapy-efficacy-for-cancer-using-routine-blood 2025-01-06T11:13:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/prediction-of-checkpoint-inhibitor-immunotherapy-efficacy-for-cancer-using-routine-blood 2025-01-06T11:13:42+00:00 hourly 0.9 https://trial.medpath.com/news/hope-therapeutics-acquires-dura-medical-to-expand-interventional-psychiatry-network-in-florida 2025-01-06T11:10:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hope-therapeutics-acquires-dura-medical-to-expand-interventional-psychiatry-network-in-florida 2025-01-06T11:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/study-finds-no-clinical-advantage-of-budesonide-inhaler-over-fluticasone-in-copd 2025-01-06T11:10:18+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-finds-no-clinical-advantage-of-budesonide-inhaler-over-fluticasone-in-copd 2025-01-06T11:10:18+00:00 hourly 0.9 https://trial.medpath.com/news/european-medicines-agency-commences-review-of-donidalorsen-in-hereditary-angioedema 2025-01-06T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-medicines-agency-commences-review-of-donidalorsen-in-hereditary-angioedema 2025-01-06T10:34:11+00:00 hourly 0.9 https://trial.medpath.com/news/open-label-randomised-clinical-trial-investigating-whether-robot-assisted-kidney 2025-01-06T10:21:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/open-label-randomised-clinical-trial-investigating-whether-robot-assisted-kidney 2025-01-06T10:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/defence-therapeutics-secures-key-patent-allowances-for-accum-r-multimer-technology-and-vaccine-platform 2025-01-06T10:09:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/defence-therapeutics-secures-key-patent-allowances-for-accum-r-multimer-technology-and-vaccine-platform 2025-01-06T10:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-optimal-age-to-stop-colorectal-cancer-screening-based-on-individual-risk-factors 2025-01-06T09:51:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-optimal-age-to-stop-colorectal-cancer-screening-based-on-individual-risk-factors 2025-01-06T09:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/the-biotech-scorecard-for-the-first-quarter-16-stock-moving-events-to-watch 2025-01-06T09:36:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-biotech-scorecard-for-the-first-quarter-16-stock-moving-events-to-watch 2025-01-06T09:36:23+00:00 hourly 0.9 https://trial.medpath.com/news/do-glp-1-receptor-agonists-increase-the-risk-of-suicide-in-patients-news-medical 2025-01-06T09:22:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/do-glp-1-receptor-agonists-increase-the-risk-of-suicide-in-patients-news-medical 2025-01-06T09:22:00+00:00 hourly 0.9 https://trial.medpath.com/news/2025-cure-parkinson-s-research-highlights-from-the-last-year-and-insights-for-the-year-ahead 2025-01-06T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/2025-cure-parkinson-s-research-highlights-from-the-last-year-and-insights-for-the-year-ahead 2025-01-06T09:08:58+00:00 hourly 0.9 https://trial.medpath.com/news/sidra-medicine-advances-innovation-and-expands-precision-medicine-efforts 2025-01-06T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sidra-medicine-advances-innovation-and-expands-precision-medicine-efforts 2025-01-06T09:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/oculis-announces-positive-ocs-05-phase-2-acuity-trial-in-acute-optic-neuritis-met-stock-titan 2025-01-06T09:02:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oculis-announces-positive-ocs-05-phase-2-acuity-trial-in-acute-optic-neuritis-met-stock-titan 2025-01-06T09:02:24+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-cell-therapy-shows-promise-for-transformed-indolent-non-hodgkin-lymphoma 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-cell-therapy-shows-promise-for-transformed-indolent-non-hodgkin-lymphoma 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/denosumab-shows-superior-fracture-prevention-in-dialysis-patients-despite-cardiovascular-risks 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/denosumab-shows-superior-fracture-prevention-in-dialysis-patients-despite-cardiovascular-risks 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/senti-bio-secures-additional-11-5-million-in-financing-to-advance-gene-circuit-based-therapies 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/senti-bio-secures-additional-11-5-million-in-financing-to-advance-gene-circuit-based-therapies 2025-01-06T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/naya-biosciences-expands-oncology-pipeline-with-new-antibody 2025-01-06T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/naya-biosciences-expands-oncology-pipeline-with-new-antibody 2025-01-06T08:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/sagimet-biosciences-to-present-fasn-inhibitor-research-at-mash-tag-2025-conference 2025-01-06T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sagimet-biosciences-to-present-fasn-inhibitor-research-at-mash-tag-2025-conference 2025-01-06T08:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/qpop-platform-shows-87-success-rate-in-personalizing-aml-treatment-selection 2025-01-06T08:04:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qpop-platform-shows-87-success-rate-in-personalizing-aml-treatment-selection 2025-01-06T08:04:02+00:00 hourly 0.9 https://trial.medpath.com/news/nuclein-achieves-dual-fda-510-k-clearance-and-clia-waiver-for-dash-r-sars-cov-2-flu-a-b-test 2025-01-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nuclein-achieves-dual-fda-510-k-clearance-and-clia-waiver-for-dash-r-sars-cov-2-flu-a-b-test 2025-01-06T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/adc-therapeutics-completes-enrollment-for-lotis-5-phase-3-trial-reinforcing-zynlonta-s-potential-in-dlbcl-treatment 2025-01-06T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adc-therapeutics-completes-enrollment-for-lotis-5-phase-3-trial-reinforcing-zynlonta-s-potential-in-dlbcl-treatment 2025-01-06T07:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/orbis-medicines-raises-eur90m-series-a-to-advance-oral-macrocycle-drug-development 2025-01-06T07:24:35+00:00 hourly 0.9 https://trial.medpath.com/zh/news/orbis-medicines-raises-eur90m-series-a-to-advance-oral-macrocycle-drug-development 2025-01-06T07:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/european-commission-ec-extends-the-approval-of-evkeeza-r-globenewswire 2025-01-06T07:10:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/european-commission-ec-extends-the-approval-of-evkeeza-r-globenewswire 2025-01-06T07:10:42+00:00 hourly 0.9 https://trial.medpath.com/news/large-meta-analysis-reveals-link-between-high-fluoride-exposure-and-reduced-iq-in-children 2025-01-06T06:35:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-meta-analysis-reveals-link-between-high-fluoride-exposure-and-reduced-iq-in-children 2025-01-06T06:35:15+00:00 hourly 0.9 https://trial.medpath.com/news/intranasal-insulin-shows-promise-in-combating-diabetes-related-cognitive-decline 2025-01-06T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/intranasal-insulin-shows-promise-in-combating-diabetes-related-cognitive-decline 2025-01-06T06:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/nmd-pharma-announces-fda-orphan-drug-designation-granted-to-globenewswire 2025-01-06T06:16:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nmd-pharma-announces-fda-orphan-drug-designation-granted-to-globenewswire 2025-01-06T06:16:16+00:00 hourly 0.9 https://trial.medpath.com/news/natural-weight-loss-drug-as-effective-as-ozempic-and-without-side-effects-academics-claim 2025-01-06T05:58:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/natural-weight-loss-drug-as-effective-as-ozempic-and-without-side-effects-academics-claim 2025-01-06T05:58:31+00:00 hourly 0.9 https://trial.medpath.com/news/opinion-the-cocktail-recipe-that-will-cure-alzheimer-s-biospace 2025-01-06T05:27:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/opinion-the-cocktail-recipe-that-will-cure-alzheimer-s-biospace 2025-01-06T05:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/evidence-mounts-for-benefit-of-glp-1s-against-heart-disease-biospace 2025-01-06T05:26:58+00:00 hourly 0.9 https://trial.medpath.com/zh/news/evidence-mounts-for-benefit-of-glp-1s-against-heart-disease-biospace 2025-01-06T05:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/a-randomized-double-blind-placebo-controlled-trial-protocol-for-a-fu-jpr-dove-medical-press 2025-01-06T05:09:19+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-randomized-double-blind-placebo-controlled-trial-protocol-for-a-fu-jpr-dove-medical-press 2025-01-06T05:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/brainstorm-advances-with-phase-3b-trial-of-nurown-r-in-als-and-secures-new-patent-for-exosome-technology 2025-01-06T05:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brainstorm-advances-with-phase-3b-trial-of-nurown-r-in-als-and-secures-new-patent-for-exosome-technology 2025-01-06T05:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/adjunctive-pcsk9-inhibitor-evolocumab-in-the-prevention-of-early-neurological 2025-01-06T04:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjunctive-pcsk9-inhibitor-evolocumab-in-the-prevention-of-early-neurological 2025-01-06T04:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/mobile-nurse-visits-show-promise-in-clinical-trials-industry-survey-reveals-91-retention-benefit 2025-01-06T03:44:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mobile-nurse-visits-show-promise-in-clinical-trials-industry-survey-reveals-91-retention-benefit 2025-01-06T03:44:23+00:00 hourly 0.9 https://trial.medpath.com/news/observational-pilot-study-of-switching-from-entecavir-to-tenofovir-alafenamide-in-patients-with 2025-01-06T03:30:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/observational-pilot-study-of-switching-from-entecavir-to-tenofovir-alafenamide-in-patients-with 2025-01-06T03:30:06+00:00 hourly 0.9 https://trial.medpath.com/news/australia-launches-a-35-7m-grant-initiative-to-enhance-clinical-trial-infrastructure 2025-01-06T02:29:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/australia-launches-a-35-7m-grant-initiative-to-enhance-clinical-trial-infrastructure 2025-01-06T02:29:15+00:00 hourly 0.9 https://trial.medpath.com/news/effect-of-intravenous-urokinase-vs-best-medicine-treatment-on-functional-outcome-for 2025-01-06T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/effect-of-intravenous-urokinase-vs-best-medicine-treatment-on-functional-outcome-for 2025-01-06T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/health-check-percheron-board-addresses-shareholders-after-failed-phase-2b-trial 2025-01-06T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/health-check-percheron-board-addresses-shareholders-after-failed-phase-2b-trial 2025-01-06T01:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/new-nmosd-treatment-gains-pbs-recommendation-ms-australia 2025-01-06T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-nmosd-treatment-gains-pbs-recommendation-ms-australia 2025-01-06T01:05:45+00:00 hourly 0.9 https://trial.medpath.com/news/strategic-r-d-resource-allocation-the-hidden-risks-of-over-investing-in-single-drug-development 2025-01-06T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/strategic-r-d-resource-allocation-the-hidden-risks-of-over-investing-in-single-drug-development 2025-01-06T01:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/guess-which-all-ords-asx-healthcare-stock-just-surged-11-on-fda-news-motley-fool 2025-01-06T00:42:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/guess-which-all-ords-asx-healthcare-stock-just-surged-11-on-fda-news-motley-fool 2025-01-06T00:42:54+00:00 hourly 0.9 https://trial.medpath.com/news/china-s-national-medical-products-administration-nmpa-approves-vyloy-markets-data 2025-01-06T00:06:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-s-national-medical-products-administration-nmpa-approves-vyloy-markets-data 2025-01-06T00:06:06+00:00 hourly 0.9 https://trial.medpath.com/news/tcl1a-protein-identified-as-predictor-of-blinatumomab-response-in-relapsed-b-all 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tcl1a-protein-identified-as-predictor-of-blinatumomab-response-in-relapsed-b-all 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gene-therapy-trial-for-geographic-atrophy-shows-limited-efficacy-despite-sustained-factor-i-expression 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gene-therapy-trial-for-geographic-atrophy-shows-limited-efficacy-despite-sustained-factor-i-expression 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/new-insights-on-hypertension-treatment-combination-pills-and-medication-timing 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-insights-on-hypertension-treatment-combination-pills-and-medication-timing 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-announces-positive-reblozyl-phase-3-results-for-mds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-announces-positive-reblozyl-phase-3-results-for-mds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/cytomed-a-singapore-biotech-revolutionizes-cancer-treatment-using-donor-immune-cells 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cytomed-a-singapore-biotech-revolutionizes-cancer-treatment-using-donor-immune-cells 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/stoke-therapeutics-to-host-webcast-to-discuss-successful 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stoke-therapeutics-to-host-webcast-to-discuss-successful 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/insulin-beats-oral-alternatives-for-gestational-diabetes-outcome 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/insulin-beats-oral-alternatives-for-gestational-diabetes-outcome 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/brentuximab-vedotin-shows-strong-real-world-efficacy-in-chinese-alcl-patients-multi-center-study-finds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/brentuximab-vedotin-shows-strong-real-world-efficacy-in-chinese-alcl-patients-multi-center-study-finds 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/technoderma-medicines-reports-positive-phase-2a-trial-results-for-tdm-180935-in-atopic-dermatitis 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/technoderma-medicines-reports-positive-phase-2a-trial-results-for-tdm-180935-in-atopic-dermatitis 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/glucarpidase-for-treatment-of-high-dose-methotrexate 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/glucarpidase-for-treatment-of-high-dose-methotrexate 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/promising-clinical-results-and-market-potential-drive-buy-rating-for-oculis-holding 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/promising-clinical-results-and-market-potential-drive-buy-rating-for-oculis-holding 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/gilead-s-trodelvy-fails-in-bladder-cancer-trial 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gilead-s-trodelvy-fails-in-bladder-cancer-trial 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/moderna-receives-fda-approval-for-rsv-vaccine-mresvia 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/moderna-receives-fda-approval-for-rsv-vaccine-mresvia 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-test-to-identify-patients-at-risk-of-opioid-use-disorder 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-test-to-identify-patients-at-risk-of-opioid-use-disorder 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/theralase-technologies-advances-bladder-cancer-treatment-with-promising-phase-ii-trial-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/theralase-technologies-advances-bladder-cancer-treatment-with-promising-phase-ii-trial-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-issues-much-anticipated-guidance-on-pulse-oximeters 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-issues-much-anticipated-guidance-on-pulse-oximeters 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/oculis-price-target-raised-to-31-from-23-at-bofa 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/oculis-price-target-raised-to-31-from-23-at-bofa 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/mepolizumab-in-chronic-rhinosinusitis-with-nasal-polyps-real-life-data 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mepolizumab-in-chronic-rhinosinusitis-with-nasal-polyps-real-life-data 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/non-opioid-pain-relievers-outperform-opioids-after-dental-surgery 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/non-opioid-pain-relievers-outperform-opioids-after-dental-surgery 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-panel-approves-sage-s-novel-antidepressant-for-postnatal-depression-rejects-alkermes-treatment 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-panel-approves-sage-s-novel-antidepressant-for-postnatal-depression-rejects-alkermes-treatment 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/citius-shares-jump-after-reporting-positive-results-from-early-study-of 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/citius-shares-jump-after-reporting-positive-results-from-early-study-of 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ptc-therapeutics-announces-fda-acceptance-for-filing-of-nda-for 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fecal-transplants-show-promise-in-alleviating-gi-symptoms-in-type-1-diabetes-patients 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fecal-transplants-show-promise-in-alleviating-gi-symptoms-in-type-1-diabetes-patients 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/i-mab-announces-portfolio-prioritization-of-givastomig-cldn18-2-x-4 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/i-mab-announces-portfolio-prioritization-of-givastomig-cldn18-2-x-4 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/tanvex-biopharma-faces-second-fda-crl-for-herceptin-biosimilar 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/tanvex-biopharma-faces-second-fda-crl-for-herceptin-biosimilar 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sage-and-biogen-s-zuranolone-shows-promise-in-phase-3-trials-but-faces-commercial-uncertainty 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sage-and-biogen-s-zuranolone-shows-promise-in-phase-3-trials-but-faces-commercial-uncertainty 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/advancements-in-retina-and-vitreous-treatments-highlighted-in-recent-studies-and-collaborations 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/advancements-in-retina-and-vitreous-treatments-highlighted-in-recent-studies-and-collaborations 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dana-farber-launches-gene-therapeutics-center 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dana-farber-launches-gene-therapeutics-center 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-advances-asundexian-to-phase-3-trials-despite-mixed-phase-2-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-advances-asundexian-to-phase-3-trials-despite-mixed-phase-2-results 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-abrysvo-for-adults-18-59-at-increased-risk-for-rsv 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-abrysvo-for-adults-18-59-at-increased-risk-for-rsv 2025-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/percheron-therapeutics-regroups-after-clinical-trial-results-vows-to-continue-to-conserve 2025-01-05T23:31:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/percheron-therapeutics-regroups-after-clinical-trial-results-vows-to-continue-to-conserve 2025-01-05T23:31:51+00:00 hourly 0.9 https://trial.medpath.com/news/ebr-systems-awaits-fda-inspection-for-wireless-cardiac-device-tipranks-com 2025-01-05T23:10:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ebr-systems-awaits-fda-inspection-for-wireless-cardiac-device-tipranks-com 2025-01-05T23:10:40+00:00 hourly 0.9 https://trial.medpath.com/news/rct-2100-by-recode-therapeutics-for-cystic-fibrosis-likelihood-of-approval 2025-01-05T21:55:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/rct-2100-by-recode-therapeutics-for-cystic-fibrosis-likelihood-of-approval 2025-01-05T21:55:51+00:00 hourly 0.9 https://trial.medpath.com/news/los-angles-shigellosis-outbreak-caused-by-mutation-vax-before-travel 2025-01-05T19:45:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/los-angles-shigellosis-outbreak-caused-by-mutation-vax-before-travel 2025-01-05T19:45:52+00:00 hourly 0.9 https://trial.medpath.com/news/dopamine-s-surprising-breakthrough-in-alzheimer-s-treatment-rolling-out 2025-01-05T19:36:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dopamine-s-surprising-breakthrough-in-alzheimer-s-treatment-rolling-out 2025-01-05T19:36:50+00:00 hourly 0.9 https://trial.medpath.com/news/cdsco-panel-approves-novartis-protocol-amendment-proposal-for-tin816-study-in-sepsis 2025-01-05T19:01:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/cdsco-panel-approves-novartis-protocol-amendment-proposal-for-tin816-study-in-sepsis 2025-01-05T19:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/lanarkshire-dad-with-mnd-backs-ps350k-campaign-to-help-fund-miracle-drug-trial-glasgow-live 2025-01-05T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lanarkshire-dad-with-mnd-backs-ps350k-campaign-to-help-fund-miracle-drug-trial-glasgow-live 2025-01-05T17:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/fda-action-update-december-2025-approval-designations-and-clinical-hold 2025-01-05T17:02:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-action-update-december-2025-approval-designations-and-clinical-hold 2025-01-05T17:02:59+00:00 hourly 0.9 https://trial.medpath.com/news/groundbreaking-mrna-vaccine-revolutionizes-pancreatic-cancer-treatment 2025-01-05T16:42:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/groundbreaking-mrna-vaccine-revolutionizes-pancreatic-cancer-treatment 2025-01-05T16:42:31+00:00 hourly 0.9 https://trial.medpath.com/news/marine-fungi-a-promising-source-of-novel-antibiotics-in-the-fight-against-drug-resistance 2025-01-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/marine-fungi-a-promising-source-of-novel-antibiotics-in-the-fight-against-drug-resistance 2025-01-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/car-t-warning-for-secondary-malignancies-warranted-or-not-medpage-today 2025-01-05T15:49:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/car-t-warning-for-secondary-malignancies-warranted-or-not-medpage-today 2025-01-05T15:49:33+00:00 hourly 0.9 https://trial.medpath.com/news/new-toolkit-shows-promise-in-improving-sickle-cell-trait-documentation-during-infancy 2025-01-05T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-toolkit-shows-promise-in-improving-sickle-cell-trait-documentation-during-infancy 2025-01-05T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/lung-protective-ventilation-guided-by-driving-pressure-improves-pulmonary-outcomes-in-nature 2025-01-05T11:37:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lung-protective-ventilation-guided-by-driving-pressure-improves-pulmonary-outcomes-in-nature 2025-01-05T11:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-s-telisotuzumab-adizutecan-shows-promise-across-multiple-solid-tumors 2025-01-05T10:00:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-s-telisotuzumab-adizutecan-shows-promise-across-multiple-solid-tumors 2025-01-05T10:00:57+00:00 hourly 0.9 https://trial.medpath.com/news/taiho-pharmaceutical-advances-astx-295-novel-mdm2-inhibitor-in-glioblastoma-and-multiple-cancer-types 2025-01-05T09:37:55+00:00 hourly 0.9 https://trial.medpath.com/zh/news/taiho-pharmaceutical-advances-astx-295-novel-mdm2-inhibitor-in-glioblastoma-and-multiple-cancer-types 2025-01-05T09:37:55+00:00 hourly 0.9 https://trial.medpath.com/news/novel-car-t-cell-therapy-scar-02-shows-promise-for-multiple-autoimmune-conditions 2025-01-05T09:37:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-car-t-cell-therapy-scar-02-shows-promise-for-multiple-autoimmune-conditions 2025-01-05T09:37:25+00:00 hourly 0.9 https://trial.medpath.com/news/genentech-advances-ro-7759065-development-for-metastatic-solid-tumors 2025-01-05T09:37:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/genentech-advances-ro-7759065-development-for-metastatic-solid-tumors 2025-01-05T09:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/abbvie-advances-novel-nlrx1-targeting-drug-amelenodor-for-inflammatory-bowel-disease-treatment 2025-01-05T09:33:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/abbvie-advances-novel-nlrx1-targeting-drug-amelenodor-for-inflammatory-bowel-disease-treatment 2025-01-05T09:33:39+00:00 hourly 0.9 https://trial.medpath.com/news/synthekine-advances-novel-il-2-based-combination-therapy-for-refractory-cll-treatment 2025-01-05T09:32:15+00:00 hourly 0.9 https://trial.medpath.com/zh/news/synthekine-advances-novel-il-2-based-combination-therapy-for-refractory-cll-treatment 2025-01-05T09:32:15+00:00 hourly 0.9 https://trial.medpath.com/news/j-j-advances-novel-liposomal-vaccine-jnj-2056-for-alzheimer-s-and-tauopathies 2025-01-05T09:10:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/j-j-advances-novel-liposomal-vaccine-jnj-2056-for-alzheimer-s-and-tauopathies 2025-01-05T09:10:45+00:00 hourly 0.9 https://trial.medpath.com/news/could-lymph-node-surgery-be-the-answer-for-treating-alzheimer-s-disease 2025-01-05T09:01:42+00:00 hourly 0.9 https://trial.medpath.com/zh/news/could-lymph-node-surgery-be-the-answer-for-treating-alzheimer-s-disease 2025-01-05T09:01:42+00:00 hourly 0.9 https://trial.medpath.com/news/dragonboat-biopharmaceutical-advances-cetuximab-biosimilar-development-for-multiple-cancer-indications 2025-01-05T08:56:22+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dragonboat-biopharmaceutical-advances-cetuximab-biosimilar-development-for-multiple-cancer-indications 2025-01-05T08:56:22+00:00 hourly 0.9 https://trial.medpath.com/news/high-fiber-diet-shows-promise-in-obesity-management-opening-new-paths-for-pharmaceutical-development 2025-01-05T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/high-fiber-diet-shows-promise-in-obesity-management-opening-new-paths-for-pharmaceutical-development 2025-01-05T06:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/china-achieves-breakthrough-in-bci-clinical-trials-enabling-patient-to-convert-thoughts-into 2025-01-05T05:51:40+00:00 hourly 0.9 https://trial.medpath.com/zh/news/china-achieves-breakthrough-in-bci-clinical-trials-enabling-patient-to-convert-thoughts-into 2025-01-05T05:51:40+00:00 hourly 0.9 https://trial.medpath.com/news/dual-biopsy-approach-enhances-precision-medicine-success-in-lung-cancer-treatment 2025-01-05T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dual-biopsy-approach-enhances-precision-medicine-success-in-lung-cancer-treatment 2025-01-05T05:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/novel-metabolic-signatures-show-promise-for-earlier-pancreatic-cancer-detection-and-prognosis 2025-01-05T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-metabolic-signatures-show-promise-for-earlier-pancreatic-cancer-detection-and-prognosis 2025-01-05T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/expert-outlines-patient-specific-approach-for-io-combinations-in-unresectable-hcc-treatment 2025-01-05T03:00:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expert-outlines-patient-specific-approach-for-io-combinations-in-unresectable-hcc-treatment 2025-01-05T03:00:41+00:00 hourly 0.9 https://trial.medpath.com/news/the-holy-grail-of-heart-health-a-valve-that-grows-inside-you-the-times 2025-01-05T01:35:24+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-holy-grail-of-heart-health-a-valve-that-grows-inside-you-the-times 2025-01-05T01:35:24+00:00 hourly 0.9 https://trial.medpath.com/news/ariad-speeding-ponatinib-to-market 2025-01-05T00:53:54+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ariad-speeding-ponatinib-to-market 2025-01-05T00:53:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-roche-s-her2-breast-cancer-diagnostic 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-roche-s-her2-breast-cancer-diagnostic 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/first-chikungunya-vaccine-approved-by-fda 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/first-chikungunya-vaccine-approved-by-fda 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/immupharma-lon-imm-stock-price-down-5-6 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/immupharma-lon-imm-stock-price-down-5-6 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/breakthroughs-in-clinical-trials-a-week-of-promising-developments 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/breakthroughs-in-clinical-trials-a-week-of-promising-developments 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/pfizer-and-lilly-s-non-opioid-pain-drug-tanezumab-shows-promise-in-phase-3-trial 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pfizer-and-lilly-s-non-opioid-pain-drug-tanezumab-shows-promise-in-phase-3-trial 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/uk-partners-with-biontech-on-clinical-trials-of-mrna-cancer-therapies 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uk-partners-with-biontech-on-clinical-trials-of-mrna-cancer-therapies 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/sava-lawsuit-alert-levi-korsinsky-notifies-cassava-sciences-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sava-lawsuit-alert-levi-korsinsky-notifies-cassava-sciences-inc-investors-of-a-class-action-lawsuit-and-upcoming-deadline 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/roche-partners-with-dicerna-for-hepatitis-b-gene-silencing-drug 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/roche-partners-with-dicerna-for-hepatitis-b-gene-silencing-drug 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/who-s-thinking-healthy-programme-shows-promise-in-treating-perinatal-depression-in-chinese-hospitals 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/who-s-thinking-healthy-programme-shows-promise-in-treating-perinatal-depression-in-chinese-hospitals 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/kadmon-prepares-fda-filing-for-gvhd-drug-belumosudil-following-phase-3-success 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kadmon-prepares-fda-filing-for-gvhd-drug-belumosudil-following-phase-3-success 2025-01-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/paxlovid-reduces-hospitalization-and-death-risks-in-covid-19-patients-with-kidney-disease 2025-01-04T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/paxlovid-reduces-hospitalization-and-death-risks-in-covid-19-patients-with-kidney-disease 2025-01-04T20:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/bms-986253-plus-nivolumab-ipilimumab-fails-to-boost-responses-in-advanced-melanoma 2025-01-04T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bms-986253-plus-nivolumab-ipilimumab-fails-to-boost-responses-in-advanced-melanoma 2025-01-04T17:08:31+00:00 hourly 0.9 https://trial.medpath.com/news/expanding-the-clinical-care-of-friedreich-ataxia-through-omaveloxlone-and-skyclarys 2025-01-04T16:03:16+00:00 hourly 0.9 https://trial.medpath.com/zh/news/expanding-the-clinical-care-of-friedreich-ataxia-through-omaveloxlone-and-skyclarys 2025-01-04T16:03:16+00:00 hourly 0.9 https://trial.medpath.com/news/efgartigimod-leads-to-sustained-myasthenia-gravis-improvement 2025-01-04T13:03:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/efgartigimod-leads-to-sustained-myasthenia-gravis-improvement 2025-01-04T13:03:09+00:00 hourly 0.9 https://trial.medpath.com/news/etanercept-and-infliximab-biosimilars-show-no-increased-infection-risk-comparable-safety 2025-01-04T12:10:32+00:00 hourly 0.9 https://trial.medpath.com/zh/news/etanercept-and-infliximab-biosimilars-show-no-increased-infection-risk-comparable-safety 2025-01-04T12:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/new-hope-for-fibrolamellar-carcinoma-summit-trial-findings-targeted-oncology 2025-01-04T12:07:03+00:00 hourly 0.9 https://trial.medpath.com/zh/news/new-hope-for-fibrolamellar-carcinoma-summit-trial-findings-targeted-oncology 2025-01-04T12:07:03+00:00 hourly 0.9 https://trial.medpath.com/news/uw-madison-pioneers-ketamine-study-for-teens-with-ptsd 2025-01-04T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/uw-madison-pioneers-ketamine-study-for-teens-with-ptsd 2025-01-04T10:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/merck-is-a-new-year-outlier-with-its-diabetes-drug-stat-news 2025-01-04T10:10:29+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-is-a-new-year-outlier-with-its-diabetes-drug-stat-news 2025-01-04T10:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/implementation-of-a-goal-directed-care-bundle-for-intracerebral-hemorrhage-plos 2025-01-04T09:48:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/implementation-of-a-goal-directed-care-bundle-for-intracerebral-hemorrhage-plos 2025-01-04T09:48:04+00:00 hourly 0.9 https://trial.medpath.com/news/kaiser-permanente-pharmacist-outlines-key-challenges-in-value-based-care-implementation 2025-01-04T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kaiser-permanente-pharmacist-outlines-key-challenges-in-value-based-care-implementation 2025-01-04T07:11:00+00:00 hourly 0.9 https://trial.medpath.com/news/nyu-perlmutter-cancer-center-combines-ai-and-community-health-workers-to-transform-clinical-trial-access 2025-01-04T06:53:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nyu-perlmutter-cancer-center-combines-ai-and-community-health-workers-to-transform-clinical-trial-access 2025-01-04T06:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/1st-stem-cell-therapy-new-hiv-drug-approved-chinadaily-com-cn 2025-01-04T06:03:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/1st-stem-cell-therapy-new-hiv-drug-approved-chinadaily-com-cn 2025-01-04T06:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/gi-cancer-treatment-faces-immunotherapy-hurdles-expert-calls-for-better-patient-education 2025-01-04T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/gi-cancer-treatment-faces-immunotherapy-hurdles-expert-calls-for-better-patient-education 2025-01-04T05:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/losartan-use-found-to-safely-ease-rdeb-symptoms-in-children-in-trial-epidermolysis-bullosa-news 2025-01-04T05:27:41+00:00 hourly 0.9 https://trial.medpath.com/zh/news/losartan-use-found-to-safely-ease-rdeb-symptoms-in-children-in-trial-epidermolysis-bullosa-news 2025-01-04T05:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/99mtc-tc-hynic-ipsma-shows-promise-in-prostate-cancer-imaging-urology-times 2025-01-04T04:19:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/99mtc-tc-hynic-ipsma-shows-promise-in-prostate-cancer-imaging-urology-times 2025-01-04T04:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/ethical-dilemma-physicians-navigate-challenges-of-repurposed-drugs-in-cancer-care 2025-01-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ethical-dilemma-physicians-navigate-challenges-of-repurposed-drugs-in-cancer-care 2025-01-04T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/incentivising-safe-sex-a-randomised-trial-of-conditional-cash-transfers-for-hiv-and-sti-prevention-in-rural-tanzania 2025-01-04T03:36:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/incentivising-safe-sex-a-randomised-trial-of-conditional-cash-transfers-for-hiv-and-sti-prevention-in-rural-tanzania 2025-01-04T03:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/pharmaessentia-corp-submits-phase-iii-clinical-trial-of-p1101-for-pre-fibrotic-early-pmf-or 2025-01-04T02:44:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/pharmaessentia-corp-submits-phase-iii-clinical-trial-of-p1101-for-pre-fibrotic-early-pmf-or 2025-01-04T02:44:10+00:00 hourly 0.9 https://trial.medpath.com/news/conventional-imaging-may-understage-prostate-cancer-new-data-suggest-urology-times 2025-01-04T01:09:02+00:00 hourly 0.9 https://trial.medpath.com/zh/news/conventional-imaging-may-understage-prostate-cancer-new-data-suggest-urology-times 2025-01-04T01:09:02+00:00 hourly 0.9 https://trial.medpath.com/news/applied-dna-sciences-advances-in-dna-technology-and-clinical-trials 2025-01-04T00:51:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/applied-dna-sciences-advances-in-dna-technology-and-clinical-trials 2025-01-04T00:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/the-pikaso-trial-a-new-hope-for-preventing-post-traumatic-osteoarthritis 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/the-pikaso-trial-a-new-hope-for-preventing-post-traumatic-osteoarthritis 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a-new-hope-for-treatment-resistant-depression-the-rise-of-psychedelic-treatments 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/a-new-hope-for-treatment-resistant-depression-the-rise-of-psychedelic-treatments 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bayer-advances-lung-cancer-therapy-into-phase-3-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/bayer-advances-lung-cancer-therapy-into-phase-3-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ucb-collaborates-with-science-37-on-virtual-clinical-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ucb-collaborates-with-science-37-on-virtual-clinical-trials 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/dengue-vaccines-and-developments-in-2025 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/dengue-vaccines-and-developments-in-2025 2025-01-04T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/benitec-biopharma-reports-positive-interim-clinical-data-for-bb-301-in-opmd-treatment-study 2025-01-03T23:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/benitec-biopharma-reports-positive-interim-clinical-data-for-bb-301-in-opmd-treatment-study 2025-01-03T23:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/sun-pharma-secures-cdsco-approval-for-novel-acid-blocker-fexuprazan-in-india 2025-01-03T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sun-pharma-secures-cdsco-approval-for-novel-acid-blocker-fexuprazan-in-india 2025-01-03T23:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/current-treatment-protocols-for-ph-all-treatment-targeted-oncology 2025-01-03T22:08:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/current-treatment-protocols-for-ph-all-treatment-targeted-oncology 2025-01-03T22:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/japan-s-mhlw-approves-takeda-s-hyqvia-subcutaneous-injection-to-treat 2025-01-03T21:47:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/japan-s-mhlw-approves-takeda-s-hyqvia-subcutaneous-injection-to-treat 2025-01-03T21:47:01+00:00 hourly 0.9 https://trial.medpath.com/news/sweden-s-mendus-clears-regulatory-path-for-vididencel-registration-trial 2025-01-03T21:36:45+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sweden-s-mendus-clears-regulatory-path-for-vididencel-registration-trial 2025-01-03T21:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/phase-3-data-show-potential-of-new-oral-treatments-for-gonorrhea-healio 2025-01-03T21:32:56+00:00 hourly 0.9 https://trial.medpath.com/zh/news/phase-3-data-show-potential-of-new-oral-treatments-for-gonorrhea-healio 2025-01-03T21:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/lpoxy-therapeutics-inc-acquires-key-assets-from-xeno-biosciences-inc-to-advance-c 2025-01-03T21:26:39+00:00 hourly 0.9 https://trial.medpath.com/zh/news/lpoxy-therapeutics-inc-acquires-key-assets-from-xeno-biosciences-inc-to-advance-c 2025-01-03T21:26:39+00:00 hourly 0.9 https://trial.medpath.com/news/coronary-sinus-reducer-an-overlooked-treatment-for-stable-angina 2025-01-03T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/coronary-sinus-reducer-an-overlooked-treatment-for-stable-angina 2025-01-03T21:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/real-world-data-shows-improved-responses-for-pembrolizumab-chemo-in-tnbc 2025-01-03T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/zh/news/real-world-data-shows-improved-responses-for-pembrolizumab-chemo-in-tnbc 2025-01-03T21:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/ticking-time-bomb-jimmy-carter-s-lasting-impact-on-cancer-breast-cancer-cvd-link 2025-01-03T20:35:11+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ticking-time-bomb-jimmy-carter-s-lasting-impact-on-cancer-breast-cancer-cvd-link 2025-01-03T20:35:11+00:00 hourly 0.9 https://trial.medpath.com/news/stem-cell-therapies-that-work-10-breakthrough-technologies-2025 2025-01-03T18:45:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/stem-cell-therapies-that-work-10-breakthrough-technologies-2025 2025-01-03T18:45:00+00:00 hourly 0.9 https://trial.medpath.com/news/landmark-va-fda-collaboration-will-compare-blood-thinners-in-new-head-to-head-clinical-trial 2025-01-03T18:31:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/landmark-va-fda-collaboration-will-compare-blood-thinners-in-new-head-to-head-clinical-trial 2025-01-03T18:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/novel-therapies-and-combinations-lead-the-way-in-women-s-cancers-in-2024 2025-01-03T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/novel-therapies-and-combinations-lead-the-way-in-women-s-cancers-in-2024 2025-01-03T18:08:34+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-drug-that-delays-onset-of-type-1-diabetes-weyi 2025-01-03T18:06:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-drug-that-delays-onset-of-type-1-diabetes-weyi 2025-01-03T18:06:51+00:00 hourly 0.9 https://trial.medpath.com/news/qurient-receives-u-s-phase-1b-approval-for-new-immunotherapy-drug-targeting-chronic-graft 2025-01-03T17:35:52+00:00 hourly 0.9 https://trial.medpath.com/zh/news/qurient-receives-u-s-phase-1b-approval-for-new-immunotherapy-drug-targeting-chronic-graft 2025-01-03T17:35:52+00:00 hourly 0.9 https://trial.medpath.com/news/merck-advances-oncology-portfolio-with-new-licensing-agreements-and-clinical-trial-updates 2025-01-03T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/merck-advances-oncology-portfolio-with-new-licensing-agreements-and-clinical-trial-updates 2025-01-03T17:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/elevation-oncology-promising-cancer-therapies-earn-analyst-praise 2025-01-03T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/elevation-oncology-promising-cancer-therapies-earn-analyst-praise 2025-01-03T17:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/addition-of-nab-paclitaxel-to-gemcitabine-cisplatin-in-advanced-biliary-tract-cancers 2025-01-03T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/addition-of-nab-paclitaxel-to-gemcitabine-cisplatin-in-advanced-biliary-tract-cancers 2025-01-03T16:59:06+00:00 hourly 0.9 https://trial.medpath.com/news/enthusiasm-for-transplant-free-strategies-for-low-risk-relapsed-hodgkin-lymphoma 2025-01-03T16:21:21+00:00 hourly 0.9 https://trial.medpath.com/zh/news/enthusiasm-for-transplant-free-strategies-for-low-risk-relapsed-hodgkin-lymphoma 2025-01-03T16:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/ai-model-can-predict-high-blood-pressure-and-related-complications-from-ecgs 2025-01-03T16:12:08+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-model-can-predict-high-blood-pressure-and-related-complications-from-ecgs 2025-01-03T16:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/mass-general-brigham-reports-results-from-trial-of-skin-cancer-prevention-therapy 2025-01-03T15:54:06+00:00 hourly 0.9 https://trial.medpath.com/zh/news/mass-general-brigham-reports-results-from-trial-of-skin-cancer-prevention-therapy 2025-01-03T15:54:06+00:00 hourly 0.9 https://trial.medpath.com/news/ocugen-will-continue-second-phase-of-ocu410-armada-clinical-trial-modern-retina 2025-01-03T15:52:27+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ocugen-will-continue-second-phase-of-ocu410-armada-clinical-trial-modern-retina 2025-01-03T15:52:27+00:00 hourly 0.9 https://trial.medpath.com/news/wockhardt-eyes-near-double-digit-margins-next-year-cnbc-tv18 2025-01-03T15:07:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/wockhardt-eyes-near-double-digit-margins-next-year-cnbc-tv18 2025-01-03T15:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/fda-approves-new-drug-for-advanced-parkinson-s-disease 2025-01-03T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/fda-approves-new-drug-for-advanced-parkinson-s-disease 2025-01-03T14:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/speckles-within-cancerous-tumors-can-determine-best-treatments-kff-health-news 2025-01-03T14:48:51+00:00 hourly 0.9 https://trial.medpath.com/zh/news/speckles-within-cancerous-tumors-can-determine-best-treatments-kff-health-news 2025-01-03T14:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/treatment-approaches-for-favorable-risk-metastatic-clear-cell-rcc-expert-perspectives-on-io-and-tki-combinations 2025-01-03T14:30:30+00:00 hourly 0.9 https://trial.medpath.com/zh/news/treatment-approaches-for-favorable-risk-metastatic-clear-cell-rcc-expert-perspectives-on-io-and-tki-combinations 2025-01-03T14:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/chime-biologics-and-mabgeek-achieve-mg-k10-ppq-milestone-advancing-atopic-morningstar 2025-01-03T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/zh/news/chime-biologics-and-mabgeek-achieve-mg-k10-ppq-milestone-advancing-atopic-morningstar 2025-01-03T14:23:01+00:00 hourly 0.9 https://trial.medpath.com/news/sky-is-the-limit-for-adc-possibilities-in-nsclc-targeted-oncology 2025-01-03T14:03:33+00:00 hourly 0.9 https://trial.medpath.com/zh/news/sky-is-the-limit-for-adc-possibilities-in-nsclc-targeted-oncology 2025-01-03T14:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/kitamaat-toddler-saved-thanks-to-clinical-trials-at-b-c-children-s-vancouver-sun 2025-01-03T14:02:50+00:00 hourly 0.9 https://trial.medpath.com/zh/news/kitamaat-toddler-saved-thanks-to-clinical-trials-at-b-c-children-s-vancouver-sun 2025-01-03T14:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/diacarta-reports-positive-clinical-trial-data-for-its-blood-based-test-to-triage-fit-pr-newswire 2025-01-03T13:57:59+00:00 hourly 0.9 https://trial.medpath.com/zh/news/diacarta-reports-positive-clinical-trial-data-for-its-blood-based-test-to-triage-fit-pr-newswire 2025-01-03T13:57:59+00:00 hourly 0.9 https://trial.medpath.com/news/amgen-s-imdyllytra-approved-by-mhra-to-treat-small-cell-lung-cancer-in-adults-pmlive 2025-01-03T13:54:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/amgen-s-imdyllytra-approved-by-mhra-to-treat-small-cell-lung-cancer-in-adults-pmlive 2025-01-03T13:54:04+00:00 hourly 0.9 https://trial.medpath.com/news/emerging-biotechs-challenge-pharma-giants-in-glp-1ra-market 2025-01-03T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/emerging-biotechs-challenge-pharma-giants-in-glp-1ra-market 2025-01-03T13:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/one-surgeon-s-spirit-and-brilliance-lift-a-whole-community-onclive 2025-01-03T13:07:28+00:00 hourly 0.9 https://trial.medpath.com/zh/news/one-surgeon-s-spirit-and-brilliance-lift-a-whole-community-onclive 2025-01-03T13:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/large-scale-study-finds-no-significant-link-between-psoriasis-and-alzheimer-s-risk-but-notes-slight-increase-in-vascular-dementia 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/large-scale-study-finds-no-significant-link-between-psoriasis-and-alzheimer-s-risk-but-notes-slight-increase-in-vascular-dementia 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/nivolumab-plus-avd-emerges-as-new-standard-for-advanced-hodgkin-lymphoma-treatment 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/zh/news/nivolumab-plus-avd-emerges-as-new-standard-for-advanced-hodgkin-lymphoma-treatment 2025-01-03T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ai-adoption-grows-in-oncology-practice-despite-validity-and-ethics-concerns-survey-reveals 2025-01-03T12:35:34+00:00 hourly 0.9 https://trial.medpath.com/zh/news/ai-adoption-grows-in-oncology-practice-despite-validity-and-ethics-concerns-survey-reveals 2025-01-03T12:35:34+00:00 hourly 0.9 https://trial.medpath.com/news/eosinophilic-esophagitis-treatment-market-2034-ema-pdma-fda-openpr-com 2025-01-03T12:34:43+00:00 hourly 0.9 https://trial.medpath.com/zh/news/eosinophilic-esophagitis-treatment-market-2034-ema-pdma-fda-openpr-com 2025-01-03T12:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/siga-s-gains-approval-in-japan-for-orthopoxvirus-treatment-therapy 2025-01-03T12:33:57+00:00 hourly 0.9 https://trial.medpath.com/zh/news/siga-s-gains-approval-in-japan-for-orthopoxvirus-treatment-therapy 2025-01-03T12:33:57+00:00 hourly 0.9 https://trial.medpath.com/news/adjuvant-immunotherapy-in-high-risk-muscle-invasive-urothelial-cancer-urotoday 2025-01-03T12:33:10+00:00 hourly 0.9 https://trial.medpath.com/zh/news/adjuvant-immunotherapy-in-high-risk-muscle-invasive-urothelial-cancer-urotoday 2025-01-03T12:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/hepatology-month-in-review-december-2024-hcplive 2025-01-03T12:04:25+00:00 hourly 0.9 https://trial.medpath.com/zh/news/hepatology-month-in-review-december-2024-hcplive 2025-01-03T12:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/takeda-s-oral-tyk2-inhibitor-matches-biologic-efficacy-drug-discovery-and-development 2025-01-03T11:43:04+00:00 hourly 0.9 https://trial.medpath.com/zh/news/takeda-s-oral-tyk2-inhibitor-matches-biologic-efficacy-drug-discovery-and-development 2025-01-03T11:43:04+00:00 hourly 0.9 https://trial.medpath.com/news/research-error-sparks-unwarranted-concerns-over-heavy-metal-content-in-prenatal-vitamins 2025-01-03T11:20:23+00:00 hourly 0.9 https://trial.medpath.com/zh/news/research-error-sparks-unwarranted-concerns-over-heavy-metal-content-in-prenatal-vitamins 2025-01-03T11:20:23+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-significant-vascular-dysfunction-in-multiple-sclerosis-patients 2025-01-03T11:15:09+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-significant-vascular-dysfunction-in-multiple-sclerosis-patients 2025-01-03T11:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/personalized-autologous-neoantigen-specific-t-cell-therapy-in-metastatic-melanoma-a-phase-1-trial 2025-01-03T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/zh/news/personalized-autologous-neoantigen-specific-t-cell-therapy-in-metastatic-melanoma-a-phase-1-trial 2025-01-03T11:06:49+00:00 hourly 0.9 https://trial.medpath.com/news/study-reveals-slower-visual-processing-in-glaucoma-patients-motor-skills-remain-intact 2025-01-03T10:51:20+00:00 hourly 0.9 https://trial.medpath.com/zh/news/study-reveals-slower-visual-processing-in-glaucoma-patients-motor-skills-remain-intact 2025-01-03T10:51:20+00:00 hourly 0.9